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 Targeted Inhibition of Histone Deacetyltransferases 
for Pancreatic Cancer Therapy 
R. Shane Laschanzky, Ph.D. 
University of Nebraska, 2019 
Supervisor: Jennifer D. Black, Ph.D. 
Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease with a dismal five-year 
survival rate of less than 10%.  One major obstacle in PDAC treatment is acquired drug 
resistance.  Pan-histone deacetylase inhibitors (pan-HDACi) are a relatively new class of 
anti-cancer drugs, with demonstrated ability to overcome drug resistance and re-
sensitize PDAC tumors to Gemcitabine (Gem).  These agents target HDACs, a family of 
18 enzymes (divided into four classes, I-IV) that catalyze the deacetylation of histones 
and other cellular proteins and have multiple effects on cell growth, differentiation, 
survival, and tumorigenesis.  Although pan-HDACi have shown significant efficacy in 
preclinical analysis, and some have been FDA approved for treatment of selected 
cancers, the results in clinical trials involving pancreatic cancer have been disappointing.  
Pan-HDACi’s are associated with serious side effects when administered at therapeutic 
doses for solid tumors, including PDAC, a limitation that is likely to account for the lack 
of clinical efficacy of these agents.  The toxicity of pan-HDACi is thought to reflect their 
ability to inhibit multiple class I, II, and IV HDACs.  With the goal of reducing this toxicity, 
selective HDAC inhibitors are being developed and are undergoing preclinical and 
clinical testing, with several of these agents receiving orphan drug status by the FDA.  
We hypothesized that targeted inhibition of a restricted number of clinically relevant 
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HDACs would recapitulate the benefits of pan-HDACi, while eliminating or greatly 
reducing dose limiting toxicities. 
 To test this hypothesis, we initially compared the effects of pan-HDACi such as 
Panobinostat with those of selective inhibitors targeting HDACs 1, 2, 3, 4, 5 and/or 6, the 
HDAC proteins known to be overexpressed in PDAC.  The HDAC inhibitor, Mocetinostat, 
was used to selectively target HDACs 1, 2, and 3, and LMK-235 was used to inhibit 
HDACs 4, 5, and 6.  Mocetinostat and LMK-235 in combination demonstrated synergy in 
multiple PDAC cell lines.  Mocetinostat/LMK-235 also synergized with Gem to suppress 
the growth/survival of PDAC cells, showing comparable synergy with that seen with the 
Panobinostat/Gemcitabine combination.  siRNA technology was used to identify the 
specific HDAC(s), i.e., HDAC1, 2, 3, 4, 5, or 6, targeted by the combination that are 
required for the observed synergy.  These experiments revealed that inhibition of only 
three HDAC proteins, HDACs 1, 2, and 6, is sufficient to recapitulate the antitumor 
effects of pan-HDACi in PDAC cells.  Notably, targeted knockdown of HDACs 1, 2, and 6 
demonstrated superior synergy with Gemcitabine than the FDA approved pan-HDACi 
Panobinostat, pointing to HDAC 1/2/6 inhibition and Gem as a promising combination for 
PDAC treatment. 
 This novel approach for PDAC treatment was tested using a combination of 
selective HDAC inhibitors: the HDAC 1 and 2 inhibitor, Romidepsin, and the HDAC6 
inhibitors, ACY-1215 (Ricolinostat) and Nexturastat.  Romidepsin is FDA approved for 
the treatment of cutaneous lymphoma and ACY-1215 is currently in phase I and phase II 
clinical trials for breast cancer and lymphoid malignancies.  Synergy was observed with 
a combination of Romidepsin and ACY-1215/Gemcitabine, and this combination showed 
improved synergy compared with the Panobinostat/Gemcitabine or Mocetinostat/LMK-
235/Gemcitabine combinations.  AnnexinV-FITC and MTT viability assays demonstrated 
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that the anti-tumor activity of the combination is partially due to an increase in apoptosis 
as well as a decrease in cellular proliferation. Studies in PDAC xenograft models show 
activity of the combination in vivo with no significant toxicity.  Together, our results point 
to targeted inhibition of HDACs 1, 2, and 6 in combination with Gemcitabine as an 
effective treatment modality for PDAC, and support further research into this 
combination for the management of pancreatic cancer in patients.   
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The Pancreas and Pancreatic Cancer 
 
Introduction 
 Despite recent advances in cancer treatment, pancreatic cancer (PaCa) remains 
a deadly disease with a 5-7% five-year survival rate and a dismal 20% one-year average 
survival after diagnosis [1].  Surgical resection of the pancreas with microscopically free 
margins before metastasis has occurred is the only known curative treatment [2].  In 
PaCa, 90% of deaths are caused by distant metastasis and over 50% of patients present 
with distant metastasis at the time of diagnosis [3]. 
 Other than family history, major predisposing factors for PaCa include: cigarette 
smoking, heavy alcohol consumption, type 2 diabetes and chronic pancreatitis [4].  Cost 
effective, non-invasive, accurate screening tools for PaCa are not currently available.  
PaCa is typically discovered late in the disease when patients present with asthenia, 
anorexia, weight loss, icterus and abdominal pain [5].  Given that patients presenting 
with advanced disease are not candidates for surgical resection, chemotherapy remains 
the best therapeutic option. 
Pancreas – Structure/Function  
 The pancreas, which has been compared to a tadpole in shape, consists of a 
head, neck, body and tail.  This spongy pinkish-grey gland is approximately six inches 
long and located posterior to the stomach, with the pancreatic head resting in the curve 
of the duodenum.  The body and the tail of the pancreas curve around and end near the 
splenic hilum [6].  Although probably best characterized as an insulin and glucagon 
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secreting endocrine gland, the pancreas serves both an endocrine and an exocrine 
function, secreting both hormones and digestive enzymes. 
 The endocrine tasks of the pancreas are carried out by a cluster of α, β, δ, and 
pancreatic polypeptide (PP) cells, collectively referred to as the “Islets of Langerhans” 
[7].  These clusters act as master regulators of blood glucose levels and contribute to 
energy metabolism through the secretion of insulin, glucagon, somatostatin, and 
pancreatic polypeptide [8].  
 The majority of the pancreas consists of exocrine pancreatic tissue [9].  The 
exocrine functions of the pancreas are carried out by two major cell types: ductal and 
acinar.  The acinar cells produce digestive enzyme precursors called zymogens [8].  The 
zymogen precursors eventually constitute lipase, protease and amylase.  These three 
enzymes act to help digest fat, protein, and carbohydrates [6].  The approximately 240 
mL of digestive juice produced daily by the acinar cells are carried to the digestive 
system through an intricate system of ducts comprised of specialized pancreatic 
epithelial cells [6]. 
 The pancreatic juice is delivered to the duodenum and eventually the digestive 
system via one of two major pancreatic ducts: the duct of Wirsung (major) and the duct 
of Santorini (minor) [9].  In addition to facilitating delivery of digestive enzymes, the 
ductal cells secrete bicarbonate to neutralize stomach acidity [10].  Interestingly, 
although 90% of new PaCa cases are classified as ductal [6] the cell of origin for 
Pancreatic Ductal Adenocarcinoma (PDAC) may not be ductal in origin.  Acinar, ductal 
or islet cells have all been hypothesized as the progenitor of PDAC with the debate 
ongoing [11].     PDAC ranks among the deadliest of cancers and is the 4th leading 
cause of cancer-related deaths worldwide.  PDAC’s high mortality rate can, in part, be 
attributed to its ability to resist chemotherapy.  PDAC ranks among the highest of the 
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chemo-resistant cancers [2].  The research described in this dissertation will focus solely 
on PDAC. 
Transformation to Cancer 
 PDAC exhibits a high degree of complexity; on average PDAC tumors carry 63 
genetic alterations in 12 core signaling pathways [12].  An abundance of research has 
been done on the pathways pancreatic cells take on their transformation into cancer.  
Despite the mutational heterogeneity between individual PDAC tumors, the progression 
from normal epithelia to dysplasia, and finally to invasive cancer is commonly linked to 
well-characterized genetic mutations.  The overwhelming majority of PDAC tumors 
contain genetic alterations of at least one of four genes: KRAS2, CDKN2, TP53, and 
SMAD4 [9]. 
 Mutation of the KRAS2, CDKN2, TP53, and SMAD4 genes is thought to occur in 
a stepwise manner, with tumor development beginning with KRAS2 activation and 
CDKN2 abrogation, followed by TP53 and SMAD4 mutation or downregulation.  KRAS2 
is a form of constitutively active RAS that acts to lock the cell in a perpetually 
proliferative state [13].  The importance of the KRAS mutation to pancreatic 
tumorigenesis is manifest by its presence in 90-99% of PDAC tumors [13, 14].  
Abrogation of the tumor-suppressor gene CDKN2, which encodes the protein p16, is 
also highly prevalent, occurring in 95% of PDAC [14].  p16 protein promotes the G1-S 
checkpoint of the cell cycle and loss of p16 contributes to unregulated growth [15]. 
 Pancreatic ductal cells next gain the ability to bypass DNA damage checkpoints 
and apoptotic signals via mutations in TP53 [16].  TP53 mutations/deletions are found in 
up to 75% of PDAC [14].  Mutations in SMAD4, which is altered in approximately 55% of 
PDAC, are believed to arise late in tumor development and promote an invasive 
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phenotype by contributing to epithelial-to-mesenchymal transition (EMT) and further 
dysregulation of extracellular signaling mechanisms [17]. 
Tumor Microenvironment  
 The genetic alterations in PDAC give rise to a highly complex tumor 
microenvironment.  Pancreas primary tumors are characteristically dense, hypoxic, and 
acidic [18].  PDAC stroma, which consists of cellular and acellular components, is 
typically so abundant as to constitute the majority of the primary tumor [18]. 
 The cellular component of the stroma consists of: endothelial cells, cancer-
associated fibroblasts (CAFs), pancreatic stellate cells (PSCs), infiltrating immune and 
inflammatory cells, as well as nervous tissue and adipocytes [19].  Quiescent PSCs are 
credited with giving rise to CAFs [20].  CAFs play a central role in malignancy; they are 
important for the establishment of an immunosuppressive microenvironment through 
secretion of growth factors and cytokines, which in turn promote tumor growth, 
metastasis and chemoresistance [19]. 
 The acellular component or extracellular matrix (commonly referred to as 
desmoplasia) consists of: hyaluronan, collagen fibers, fibronectin, proteoglycans, 
hyaluronic acid, as well as growth factors, cytokines, proteinases and other enzymes 
[18].  PSCs secrete collagen and other components of the extracellular matrix in 
response to growth factors, such as, TGFβ1 and platelet-derived growth factor (PDGF) 
[21].  Interestingly, PSCs also regulate the reabsorption and turnover of the ECM via 
secretion of metalloproteinases [22]. 
 In addition to the general sparsity of vasculature in PDAC stroma, the ECM 
creates a physical barrier to drug delivery via constriction of the intratumoral micro- 
vessels [23].  Interestingly, although there is an abundance of evidence of stromal 
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involvement in drug resistance and tumor promotion [24], multiple studies have 
demonstrated that therapeutic depletion of the ECM does more harm than good, with 
ablation of PSCs and CAFs accelerating metastasis and reducing survival in PaCa 
mouse models [25-27]. 
Current First-Line Chemotherapy Options  
 Currently, PDAC is treated by one of two first line therapies: FOLFIRINOX, or a 
combination of gemcitabine and Abraxane [2]. 
 Gemcitabine (Gem) is a synthetic pyrimidine nucleoside prodrug, a nucleoside 
analog in which the hydrogen atoms on the 2’ carbon of deoxycytidine are replaced by 
fluorine atoms. Considered an anti-metabolite because of its ability to become 
incorporated into DNA and halt replication, Gem was originally approved as a single first-
line agent for PDAC therapy [28].  Additionally, Gem is demonstrated to be a nucleoside 
metabolic inhibitor with the mechanism of action being to abrogate nucleic acid synthesis 
[29].  Typically, patients are treated with Gem via slow-drip intravenous injection at 1000 
mg/m2 on days 1 and 8 of a 21 day treatment cycle [29].  The most common dose-
limiting toxicities are neutropenia, and myelosuppression, and the Gem dose can be 
reduced by 75% to combat these side effects [29].  Patients treated with single agent 
Gem experienced an average of 6 months of additional life [28, 30]. 
 The introduction of FOLFIRINOX in 2010 provided PDAC patients with the first 
viable alternative to Gem that could offer improved results.  FOLFIRINOX is a 
combination of 3 chemotherapeutic agents plus a derivative of vitamin B.  The name 
FOLFIRINOX itself is an acronym which represents: folinic acid (FOL) – a vitamin B 
derivative included to combat the side effects of fluorouracil, fluorouracil (F) – a DNA 
damaging agent and antimetabolite which halts DNA synthesis, irinotecan (IRIN) – a 
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topoisomerase inhibitor, and oxaliplatin (OX) – a platinum-based antineoplastic, 
regarded as a DNA damaging agent, which eventually leads to inhibition of DNA 
synthesis and repair [31]. 
 Patients treated with FOLFIRINOX enjoy a significant improvement in survival, 
with an average of 11.1 months compared with 6.8 months for Gem [32].  Unfortunately, 
FOLFIRINOX is also associated with increased adverse events, including grade 4 
neutropenia, febrile neutropenia, thrombocytopenia, diarrhea and sensory neuropathy.  
Because of its increased toxicity, FOLFIRINOX is only recommended to patients 
exhibiting a good performance status [32]. 
 Fortunately for PDAC patients for whom FOLFIRINOX is not a viable option, a 
combination of Gem and Abraxane (Gem-Abraxane) is now available.  Treatment with 
Gem-Abraxane improved median survival time to 8.5 months over 6.7 months for Gem 
alone, and improved the one-year survival rate of patients by 13% (35% vs. 22%) [33].  
Additionally, Gem-Abraxane demonstrated a survival benefit and increased quality of life 
in patients exhibiting a poor performance status [34].  Unfortunately, Gem-Abraxane 
treatment still exhibits significant toxicity, including grade 3/4 neutropenia, leukopenia, 
neuropathy, febrile neutropenia, and fatigue [34]. 
 Abraxane is comprised of Paclitaxel (a taxane) bound to albumin.  The taxane 
class of drugs targets and kills dividing cells.  The method of action involves binding to 
tubulin, which effectively abrogates mitosis and intracellular protein transport [35].  
Albumin protein is bound to Paclitaxel to increase solubility and absorption [2].  Gem-
Abraxane’s efficacy was originally thought to be based on a synergistic effect between 
the two drugs, brought about by their ability to target mitotic cell division via different 
mechanisms.  Surprisingly, however, the observed synergy appears to result from 
Abraxane’s ability to increase intra-tumoral Gem concentration through a mechanism 
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that is not fully understood [36].  Combination therapy, drug resistance, and toxicity will 
be further discussed in subsequent chapters of this work. 
 
Conclusion 
 The human pancreas is a complex organ which serves an endocrine and 
exocrine function.  The endocrine pancreas acts as a regulator of blood glucose 
concentration, while the exocrine pancreas secretes zymogens which eventually 
become the enzymes responsible for lipid, protein, and carbohydrate digestion. 
 Although relatively rare, tumors of the pancreas are devastating, and their 
incidence is increasing.  Surgical resection before metastasis is the only curative 
treatment.  Due to a lack of screening tools and an absence of early symptoms, most 
patients present with late-stage unresectable disease.  Effective chemotherapies remain 
the best hope for the majority of pancreatic cancer patients. 
 Over 90% of pancreatic cancers arise in the ducts of the exocrine pancreas [37].   
Ductal tumors are associated with significant scarring and desmoplasia.  The acellular 
component of PDAC typically constitutes most of the tumor volume and is associated 
with PDAC’s chemo-resistant nature.  Unfortunately, depletion of the stroma worsens the 
disease, revealing the dynamic and complex nature of this tumor. 
 Combination therapies offer the most effective option for advanced stage 
patients; however, these treatments are associated with increased toxicity that many 
patients are not able to tolerate.  Furthermore, even though combination treatment offers 
the best outcome, they still on average only provide less than one year of additional life.  
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Effective, less toxic new treatments are desperately needed to combat this devastating 
disease.  
  
Drug Resistance, Combination Therapy and HDACi 
 
Introduction 
 Drug resistance is a hallmark of PDAC.  One major strategy to combat drug 
resistance has been combination chemotherapy.  The success of both FOLFIRINOX and 
Gem-Abraxane is testament to the benefit of this strategy.  Unfortunately, although 
combination regimens have provided improved results in PDAC patients, drug 
combinations are almost uniformly associated with increased toxicity over single-agent 
treatment.  Multiple clinical trials have been abandoned, not because of lack of efficacy, 
but because of dose limiting toxicities. 
 The realization that epigenetic dysregulation could be a driver of PDAC sparked 
intense research into drugs targeting different regulators of the epigenome.  
Accumulating evidence indicates that drugs targeting epigenetic changes, specifically 
HDAC inhibitors (HDACi), can prevent or reverse drug resistance.  Thus, this new area 
of study opens the possibility of a low dose combination regimen that may avoid many of 
the toxicities of other combination therapies. 
Drug Resistance 
 Inherent and acquired drug resistance is arguably the greatest obstacle clinicians 
face in treating PDAC.  Drug resistance is credited as being the most common reason 
for discontinuation of treatment [38]. 
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 Desmoplasia and the restrictive tumor microenvironment act to prevent 
chemotherapeutic agents from accessing the PDAC cells and are a major factor in 
inherent drug resistance.  Unfortunately, as mentioned above, depletion of the tumor 
microenvironment leads to increased metastasis and a worse prognosis.  Inherent drug 
resistance is also attributed to the heterogeneity of PDAC.  Studies have demonstrated 
that even the smallest clinically detectable tumor, at about 109 tumor cells, will still 
contain approximately 1,000 drug resistant cells [39].  These 1,000 cells are enough to 
re-populate the tumor after the drug-sensitive cells have been destroyed. 
 In addition to the inherent drug resistance of PDAC cells, acquired drug 
resistance is also in play.  Reduced drug uptake and increased drug efflux after 
exposure to chemotherapy are prevalent in PDAC [40, 41].  Chemotherapy often results 
in an increased expression of efflux proteins, including members of the multidrug 
resistance protein family (ATP-binding cassette, subfamily C (ABCC) multidrug 
transporters) [39, 41].  In relation to Gem, a pyrimidine nucleoside analog, drug uptake is 
inhibited by mutations, deletions, or down-regulation of nucleoside transporters, or the 
upregulation of nucleoside phosphatases which can lead to the inactivation and 
degradation of gemcitabine [40, 42].  Unfortunately, research has demonstrated that 
PDAC tumors begin adapting to chemotherapies such as Gem within two weeks of initial 
treatment [43].  Although not all tumors are able to adapt quickly enough to avoid 
destruction, the cells that are able to acquire a resistant phenotype will quickly re-
populate the tumor. 
Combination Therapy and HDACi 
 Clinicians and researchers have attempted to overcome the drug resistance 
conundrum in PDAC with combinatorial approaches.  Two major combination strategies 
have emerged. Initial approaches involved using different drugs to target a single 
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process or pathway.  Subsequently, as more diverse and precise therapies became 
available, researchers began to target different pathways simultaneously. 
 The combination of the antimetabolite Gem and the mitotic spindle disruptor 
Abraxane is an example of targeting two individual aspects (i.e., DNA replication and 
mitosis, respectively) of the same process: cell division.  The drug combination 
FOLFIRINOX is another example, with three separate chemotherapeutic drugs acting to 
induce DNA damage and inhibit DNA replication.  Unfortunately, as previously covered 
in this work, significantly increased toxicity plagues this combination strategy.   
 Examples of combination therapies targeting two or more disparate processes, 
all of which are critical to a cancer cell’s survival/proliferation, include EGFR inhibitors 
with Gem [44, 45] and the HER2 pathway inhibitor, lapatinib, with Gem [46].  In contrast 
to single process targeting, combination therapies that target more than one pathway are 
not plagued by toxicity but are limited by lack of efficacy.  Unfortunately, the survival 
benefit of these combination trials has been measured only in weeks.  Thus, a third 
strategy is now being explored: epigenetic disruption in combination with chemotherapy. 
Histone Deacetylase Inhibitors  
 HDACi are a relatively well described class of drugs that have been utilized in a 
wide range of diseases including: mood disorders and depression, cardiovascular 
diseases, parasitic infection, inflammatory disease, and cancer [47] 
 The potential for cancer treatment is a relatively new development in the HDACi 
story.  HDACi are attractive for cancer therapy because they have demonstrated 
selective toxicity to cancer cells over normal cells in vitro and in vivo [48, 49].  The 
selectivity of HDACi for tumor cells over non-transformed cells appears to stem from a 
defective G2 cell cycle checkpoint, which is re-activated with HDACi treatment [50].  
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Accumulating evidence further indicates that HDACi may also target non-proliferating 
tumor cells by promoting apoptosis [51].  Perhaps most significantly, HDACi have 
demonstrated significant synergy with Gem [52, 53] and this synergy could, in part, be 
attributed to the reversal of acquired drug resistance [52, 54-56].  This discovery has led 
researchers to study the interaction between HDACi and Gem in PDAC, with the hope of 
designing an ideal drug combination.   
 HDACi can be divided into two broad classes: pan-HDACi and specific HDACi.  
While the pan-HDACi target multiple classes of the HDAC family, the specific-HDACi 
target specific classes of HDACs or even individual HDAC proteins.  An in-depth 
description of the different HDAC proteins is provided in Section 3 of this work.  As a 
general rule, HDACi occupy the zinc binding pocket of the HDAC catalytic site [57] and 
are categorized by the structure of their zinc binding group.  The seven major classes of 
HDACi are: hydroxamic acids, benzamides, carboxamides, cyclic peptides, 
hydroxyacrylamides, isothiocyanates, and short chain fatty acids [58]. 
 The prototypical HDACi, butyric acid (a short chain fatty acid) was discovered as 
a natural product of bacterial fermentation of dietary fiber in the large bowel [59].  The 
anti-neoplastic effects of butyric acid were observed soon after its ability to modify 
histones was described.  However, it was not until much later that its mechanism of 
action was elucidated.   
 In 1977 and 1978, butyric acid was reported to be a potent effector of histone 
modification [60, 61] and an inhibitor of histone deacetylation [62, 63].  Shortly 
afterwards, it was discovered to significantly increase apoptosis in cancer cells in culture 
[64].  Given its ability to function as a nuclear disrupter and anti-neoplastic agent, butyric 
acid has been utilized in the laboratory for decades; however, it was not viewed as a 
naturally occurring anti-cancer agent [65] until the discovery that animals fed diets rich in 
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fiber produced significant amounts of butyric acid in the colon [66].  The link between 
high-fiber diets and reduced rates of colon cancer could be explained by increased 
exposure of pre-neoplastic and neoplastic cells to butyric acid [67]. 
 Although the ability of butyric acid to inhibit histone acetylation was known in the 
late 1970s, its mechanism of action as an HDACi was not realized until much later.  It 
wasn’t until 1996 that Tauton, Hassig, and Schreiber isolated and cloned the first HDAC 
protein (HDAC1) in humans [68].  In 1999 Finnin and colleagues reported that the pan-
HDACi, Trichostatin A and Vorinostat, both worked to increase histone acetylation by 
inhibiting the catalytic site of the classical HDACs [69].  Soon after, in 2003, Davie et al. 
described butyric acid as an HDACi [70].  The notion that a naturally occurring HDACi 
could prevent and treat cancer led to an explosion of research into HDACi. 
 Interestingly, in addition to butyric acid, the four clinically available HDACi that 
are FDA approved for cancer treatment (Belinostat, Panobinostat, Romidepsin, and 
Verinostat) are all derivatives of molecules originally discovered in microorganisms [71]. 
The secretion of HDACi by bacteria is thought to be a defense mechanism against 
eukaryotic organisms [72].  Strong supporting evidence for this notion comes from the 
use of Trichostatin A, a hydroxamic acid produced by S. hygroscopius, as a potent 
antifungal antibiotic [73].  Additionally, HDACi are secreted or produced by a broad 
range of organisms, including archaebacteria, eubacteria, fungi, and plants [71], adding 
to the sophisticated evolutionary interaction between HDACi producers and their target 
organisms.    
 The idea that HDACi are a natural product that eukaryotes have evolved with 
may help to explain why HDACi show selectivity for cancer cells over non-transformed 
cells.  Complex conserved evolutionary pathways are beginning to be elucidated that 
demonstrate the ability of eukaryotes to overcome HDACi effects [74].  The most 
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intriguing evidence of the intrinsic ability of eukaryotic cells to overcome HDAC inhibition 
comes from studies on human lymphoblastoid cells exposed to the HDAC inhibitor 
Vorinostat for 30, 60, and 120 minutes.  The study’s authors discovered that exposure to 
Vorinostat resulted in rapid downregulation of genes encoding components of six 
enzyme complexes responsible for lysine acetylation (the KAT complexes) [75].  Early 
evidence from this work  is pointing to disruption of HDAC inhibitor compensatory 
pathways as hypersensitivity of some cancers or cancer cell lines to HDACi. 
Pan-HDACi in PDAC Treatment  
 Apart from Romidepsin, all HDACi FDA approved for cancer treatment are pan-
HDACi.  The four HDACi that are FDA approved for cancer treatment are used for the 
treatment of hematological malignancies [76].  At therapeutic doses for hematologic 
malignancies, HDACi have been associated with a wide range of adverse effects 
including nausea, vomiting, fatigue, rash, cough, fever, headache, and anorexia.  
However, these side effects are typically not severe enough to warrant discontinuation of 
treatment [76].  Unfortunately, at the higher doses required to treat “solid tumors,” dose 
limiting toxicities are observed. 
 Of the three FDA approved pan-HDACi, Panobinostat (hydroxamic acid) is more 
potent then Belinostat or Vorinostat.  Panobinostat demonstrates a significantly longer 
elimination time, prolonged hyperacetylation of histone protein and more prominent 
modulation of gene expression [77].  The increased potency and elimination time of 
Panobinostat allows clinicians to utilize intermittent dosing schedules with the intention 
of reducing off-target effects [77].  The advantages of Panobinostat over Belinostat and 
Vorinostat have made Panobinostat the drug of choice for mono- and combination 
therapies in PDAC. 
26 
 
 Three major side effects are associated with pan-HDACi: myelosuppression, 
cardiac toxicity, and severe diarrhea [76].  Unfortunately, clinical trials utilizing 
Panobinostat have had to be terminated early because of severe treatment-related 
toxicity including neutropenia, thrombocytopenia, tachycardia, and grade 3/4 diarrhea 
[78].  Although the clinical trials utilizing single agent Panobinostat were terminated 
prematurely due to dose limiting toxicities, positive treatment responses such as delays 
in tumor growth, reduced metastasis, and a reduction in tumor burden were observed 
[78].  These mixed results suggested that HDACi may provide a viable therapeutic 
option in PDAC, but only if the toxicity can be managed.   
Panobinostat in Combination with Gemcitabine in PDAC 
 Research using PDAC cell culture models demonstrated that pan-HDACi 
synergize with Gem [52, 53].  Surprisingly, the studies also demonstrated pan-HDACi 
treatment yeilded increased efficacy after tumor cells acquire Gem resistance [55].  Early 
evidence suggested the significant synergy observed between HDACi and Gem is due 
to the ability of HDACi to up-regulate the cyclin-dependent kinase inhibitor p21 
independently of p53 [79]. 
 Gem treatment of PDAC tumor cells is associated with arrest in the G1 phase of 
the cell cycle [80].  In contrast, increased expression of p21, a hallmark of pan-HDACi 
treatment [81], is associated with arrest in both the G1 and G2/M checkpoints [82, 83].  
Panobinostat’s ability to arrest the cell cycle in both the G1 and G2/M checkpoints (see 
Figure 7 below) may overcome the ability of PDAC cells to escape G1 arrest.  
Panobinostat also drives PDAC cells to undergo apoptosis via up-regulation of the pro-
apoptotic proteins, Bax, Bak, and Bim, and down-regulation of anti-apoptotic XIAP, Mcl-
1, and Bcl-2 proteins [78, 84, 85].  The ability of Panobinostat to induce apoptosis is 
most likely a significant factor in its synergy with Gem, given that Gem only targets 
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dividing cells. HDACi treatment also alters the expression of membrane transport 
proteins associated with Gem resistance [55, 86, 87] and this may be a major contributor 
to the ability of HDACi to reverse acquired drug resistance in Gem-treated cells. 
 The laboratory work on pan-HDACi in PDAC has translated to partially 
successful clinical trials, with patients experiencing significant survival benefits over 
chemotherapy or HDACi alone [79].  Unfortunately, clinical trials of pan-HDACi in 
combination with Gem have elicited similar dose limiting toxicities to single agent HDACi 
monotherapies, including myelosuppression and grade 4 diarrhea [88].  Given the 
clinical evidence, pan-HDACi combination therapy does not arrear to be a viable option 
for PDAC treatment. 
Selective HDACi in PDAC Treatment 
 A battery of selective HDACi have been developed and these agents are being 
used both in research as well as in clinical settings.  As a more comprehensive 
understanding of the HDAC proteins is realized (covered in next chapter), it has become 
apparent that pan-HDACi should be utilized as proof-of-principle tools and not in clinical 
treatment.  Pan-HDACi toxicities are almost certainly related to their broad spectrum 
HDAC inhibition.  The generally low toxicity of selective-HDACi indicates that inhibition of 
specific HDAC proteins can be accomplished without adverse effects. 
 The toxicity of the selective-HDACi depends upon the HDACs targeted.  HDAC6 
for example, can be deleted in mice with very minimal impact [89].  Not surprisingly, 
HDAC6 inhibitors are non-toxic [90, 91]; however, not all specific-HDACi are non-toxic.  
The FDA approved drug Romidepsin, a selective inhibitor of HDAC1 and HDAC2 elicits 
significant adverse effects, including sudden death, when used at therapeutic doses for 
solid tumors [76]. 
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The Histone Deacetylase Proteins 
 
Introduction 
 The histone deacetylase (HDAC) proteins are a group of enzymes best known 
for their ability to remove acetyl groups from the N-terminal tails of histone proteins, 
resulting in epigenetic regulation of gene transcription.  Deacetylation of histones, for 
which the HDACs are named, is likely not their primary function.  The HDAC proteins 
have been grouped into four classes (I-IV), all of which have been identified in all fully 
sequenced free-living eukaryotic organisms (excluding fungi).  Class I, II, and IV HDACs 
also exist in eubacteria and class II HDACs have been identified in archaebacteria.  
Phylogenetic analysis suggests that class II HDAC proteins existed in the common 
ancestor of all extant forms of life [92].  Although organisms as ancient as the Archaea 
bacteria utilize histone like proteins to package their DNA into layered hypernucleosome 
type structures, these histones lack the N-terminal tail region and have not been 
demonstrated to be acetylated [93].  Given their ubiquitous expression among 
prokaryotes including the Archaea, HDAC proteins almost certainly predated histone 
proteins. 
 Acetylation/deacetylation of non-histone proteins is critical for protein activation, 
deactivation, phosphorylation, methylation, ubiquitination, sumoylation, as well as protein 
folding and turnover [94, 95].  The ability of HDACs to deacetylate non-histone proteins 
is well documented; however, the realization that non-histone protein deacetylation could 
be a primary function of the HDACs is relatively new.  Understanding of the significant 
role of HDACs in non-histone protein regulation led to an increased appreciation for the 
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intracellular location, proteins/processes involved in HDAC shuttling, and the 
structural/functional and tissue diversity of HDAC proteins.  The recent recognition of the 
role of HDACs as global protein regulators has revolutionized how researchers have 
approached HDAC regulatory functions in gene expression as well as the potential of 
HDAC inhibitors for the treatment of human disease, including cancer. 
 
Acetylation Status and Gene Transcription  
 A major factor in gene transcription is access.  For transcription to occur, the 
transcription machinery, as well as ancillary proteins, need access to target genes.  
Multiple epigenetic mechanisms exist to regulate protein expression via transcriptional 
control; one of the best studied and characterized is modification of the N-terminal tails 
of histone proteins. 
 In eukaryotic organisms, a stretch of 147 base pairs of DNA is wrapped around a 
histone octamer, comprised of an H3-H4 tetramer and two H2A-H2B dimers.  This 
protein/DNA complex is referred to as the “nucleosome”.  Nucleosomes are then linked 
together by a third histone protein (H1), forming a 30nm solenoid structure commonly 
referred to as chromatin [96].  Chromatin can be further divided into the “open” or 
transcriptionally active euchromatin, and the “closed” or transcriptionally inactive 
heterochromatin. 
 Heterochromatin is DNA in its most protected and compact state.  For the DNA to 
be assembled into heterochromatin, it must be folded into close proximity with itself.  The 
histone proteins in the nucleosome are bound to the DNA via an electrostatic attraction 
between the negatively charged phosphate backbone of the DNA and the positively 
charged amino acid residues in the core globular histones.  For full DNA compaction into 
30 
 
heterochromatin, however, the intrinsic negative charge of the DNA must be overcome, 
and the nucleosome core particle cannot accomplish this task.  Possessing a charge of 
+144e, the core histone complex is not able to neutralize the -294e charge of the 147 
base pairs of DNA wrapped around it, leaving the nucleosome with a net charge of -
150e [97].  For the DNA to fully condense into heterochromatin, the positively charged 
lysine residues of the histone tails are required.  In contrast, “opening up” or “relaxing” 
the heterochromatin into euchromatin is achieved by neutralization of the positively 
charged lysines on the N-terminal tails [98]. 
 The N-terminal histone tails act as a major epigenetic regulator of gene 
transcription, and can undergo at least 12 different types of post-translational 
modifications including: acetylation, methylation, phosphorylation, sumoylation, 
ubiquitination, ADP ribosylation, butylation, citrullination, crotonylation, formylation, 
proline isomerization and propionylation [99].  In this dissertation, analysis will focus on 
acetylation.   
 Acetylation occurs when histone acetyltransferase (HAT) proteins transfer the 
acetyl moiety of acetyl-CoA to the ϵ-amino group of lysine residues.  Removal of acetyl 
groups from the histone tails is accomplished by HDACs.  This is a highly conserved and 
ubiquitous process, described in every eukaryote examined [100].  The acetylation state 
of histone tails has been directly and indirectly correlated to gene transcription by 
dictating higher order chromatin structure and recruitment of transcriptional enzyme 
complexes to specific regions of the genome [101].  Histone acetylation is also extremely 
transient, with the average half-life of an acetyl-lysine being 60-120 minutes [102].  This 
makes acetylation among the most temporary regulators of gene transcription.  The 
acetylation state of chromatin is in perpetual flux, dictated by the number of HAT and 
HDAC proteins as well as their co-repressor, co-activator and targeting proteins [103].  
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Recent advances in the understanding of epigenetics, combined with targeted 
pharmacologic inhibitors, have made the HDAC proteins an exciting target for disease 
research.  
 
The 18 Human HDACs 
 The HDAC proteins can be divided into two major groups: the classical or metal- 
dependent HDACs and the sirtuins.  The division is based upon the enzymatic co-factor 
utilized in the deacetylation reaction.  The sirtuins, or class III HDACs, utilize NAD+ as a 
reactant for deacetylation.  The classical HDACs (class I, II, and IV) utilize zinc as a co-
factor.  The research described in this dissertation focuses solely on the classical 
HDACs (Figure 1). 
 The classical HDAC enzymes share a highly conserved 390 amino acid catalytic 
domain, which utilizes an ion of zinc to bring the carbonyl carbon of the acetyl group into 
proximity with a molecule of water for nucleophilic attack.  Upon termination of the 
deacetylase reaction, the acetyl group is dissociated as carboxylic acid and the lysine 
residue is returned to its positively charged state [69]. 
 In humans, the HDAC family consists of 18 proteins: 11 classical HDACs and 7 
sirtuins.  The 11 classical HDACs are further subdivided into three major classes: I, II, 
and IV.  Individual classes are further categorized into sub-classes designated a and b.  
The HDAC classes were named after their similarity to yeast proteins.  Class I HDACs 
most closely resemble the yeast Rpd3 protein and the class II HDACs resemble yeast 
Hda1.  The class IV HDACs demonstrate a mixture of both class I and class II 
characteristics [92]. 
32 
 
 
 
 
 
Figure created from referenced works[103-108] 
  
33 
 
The conservation of HDAC classes across divergent organisms points to non-
redundant roles of these groups of enzymes [92].  However, significant overlap in 
function and structure is observed within each class, and HDACs do not usually perform 
their enzymatic function independently.  As a rule, HDAC proteins are extremely 
interdependent and are typically members of large multi-protein complexes which  
include other HDACs as well as regulatory and scaffolding proteins.  A brief review of 
each individual HDAC as it relates to its class and sub-class is provided.   
Classes, Subclasses, and Individual HDACs 
 Class I – The class I HDACs include HDACs 1, 2, 3 and 8 and have been 
demonstrated to account for over 50% of the histone deacetylase activity in embryonic 
stem cells [109].  Class I HDACs are, in general, ubiquitous in expression [110] and 
primarily located in the nucleus.  A major hallmark of this class is participation in large 
stable multiprotein complexes, although recent work has demonstrated that HDAC1 (and 
possibly all the class I HDACs) is able to directly bind chromatin [111].  These 
complexes are typically recruited to DNA via transcription factors and DNA binding 
proteins [98].  The cell utilizes these protein complexes to target class I HDAC activity to 
specific regions of the genome and the dependence on large protein complexes allows 
for strict regulation.  It is not surprising that the deacetylase activity of the class I HDACs 
is greatly reduced when they are in isolation [112]. 
 The class I HDACs are further subdivided into class Ia (HDAC1 and 2) and class 
Ib (HDAC3 and 8).  As previously stated, significant overlap is observed within HDAC 
subclasses.  HDACs 1 and 2 share 82% amino acid identity [113] and will typically 
associate to form heterodimers.  HDACs 1 and 2 are best characterized in four major 
complexes: NuRD, Sin3, CoREST and MiDAC [114].  The protein complexes serve very 
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diverse functions, which are still being described.  For example, the NuRD complex is 
recruited by the polycomb and hunchback repressors and is involved in silencing large 
clusters of genes.  In contrast, Sin3 is recruited via nuclear hormone receptors and is 
associated with silencing specific genes [115]. 
 Although HDACs 1 and 2 are very similar both in structure and function, they 
undoubtedly serve some disparate functions.  Studies have demonstrated that 
homozygous deletion of HDAC1 in mice is embryonically lethal [116, 117], whereas mice 
with homozygous deletion of HDAC2 survive until the perinatal period, eventually 
succumbing to multiple cardiac defects [117].  Like the class Ia HDACs, class Ib HDACs 
(HDACs 3 and 8) participate in multi-protein, multi-HDAC targeted complexes.  However, 
members of class Ib differ from those of class Ia in that HDAC3 and 8 do not share 
significant sequence homology [92] and are typically not found together. 
 HDAC8 differs significantly from its class I cohorts.  Phylogenetic analysis has 
indicated that HDAC8 is restricted to vertebrates [92].  Unlike its peers, HDAC8 is tissue-
specific and is expressed almost exclusively in the cytosol of smooth muscle [94].  Most 
interestingly, HDAC8 appears to have evolved a preference for potassium or sodium 
over zinc as its monovalent cation co-factor [118]. 
 Unlike HDAC8, HDAC3 is considered the only vertebrate member of an ancient 
invertebrate subclass and is widely expressed in tissues [92].  Although it is ubiquitously 
expressed, HDAC3’s activity is actually regulated by additional tissue specific HDACs.  
Interestingly HDAC3 appears to provide the deacetylase action for the entire HDAC 
class IIa subgroup.  An extensive characterization of the HDAC3/class IIa interaction will 
be covered later in this work.  In addition to the class IIa HDACs, HDAC3 relies upon 
binding to two major co-repressor complexes for enzymatic activity: SMRT (silencing 
mediator for retinoid and thyroid receptors) and N-CoR (nuclear receptor corepressor) 
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[107] (Fig. 1).  The SMRT/N-CoR co-respressors contain a deacetylase activation 
domain (DAD) which is exclusively required for HDAC3 enzymatic activity [119, 120].  
The SMRT/N-CoR/HDAC3 complex also dictates HDAC3’s intracellular location.  Unlike 
its other class I cohorts, HDAC3 contains both an NLS (nuclear localization signal) and 
an NES (nuclear export signal) (Figure 1). The SMRT/N-CoR complex, in conjunction 
with the class IIa HDACs, is responsible for shuttling and targeting HDAC3 to its desired 
intracellular location [105, 121].   
HDAC3 has been extensively characterized as being essential for DNA double 
strand break repair.  Inactivation of HDAC3 in mouse embryo fibroblasts (MEFs) resulted 
in defects in non-homologous end joining after ionizing radiation exposure [122].  
Additionally, when siRNA is utilized to knock down HDAC3 in mitotically active HEK 293 
cells, the homologous recombination pathway utilized to repair double strand DNA 
breaks is inhibited [123]. 
Class II – The class II HDACs include HDAC4, 5, 6, 7 ,9 and 10 and are 
significantly more tissue-specific than class I enzymes [124].  With the exception of 
HDAC6, which is almost entirely cytoplasmic [125], the class II HDACs shuttle between 
the nucleus and the cytoplasm [94].   
Class IIa enzymes (HDAC4, 5, 7 and 9) contain distinct N-terminal and C-
terminal domains and, surprisingly, are catalytically inactive due to a tyrosine-to-histidine 
mutation in the deacetylase domain [126, 127].  Instead of direct deacetylase activity, 
the class IIa HDACs function as activating, coordinating and targeting proteins for 
HDAC3 [126].  The catalytically inactive HDAC domain of the class IIa HDACs binds to 
the RD3 region of SMRT/N-CoR (Fig 1) [128].  Upon binding to the SMRT/N-
CoR/HDAC3 complex, class IIa HDACs utilize an approximately 600 amino-acid N-
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terminal extension as platform for additional protein-to-protein interactions and post 
translational modifications [129].   
Each of the four different class IIa HDACs contains a novel N-terminal regulatory 
domain, with an overall sequence homology between individual class IIa HDACs of only 
30-45% [106].  The diversity of the N-terminal regulatory domains allows for a wide array 
of regulatory proteins to indirectly interact with and target HDAC3, with the best 
characterized being the MEF2 (myocyte enhancer factor) DNA anchoring transcription 
factors [106]. 
 In addition to the N-terminal regulatory domain, the class IIa HDACs contain a 
binding site for 14-3-3 nuclear export protein, which can be activated by phosphorylation 
via multiple kinases such as protein kinase D and salt inducible kinase (SIK) [130].  
Interaction with 14-3-3 protein results in cytoplasmic retention of the complex and 
prevention of histone modification and subsequent transcriptional suppression of genes 
targeted by the class Ila complex [131].  Dephosphorylation via phosphatases such as 
PP1, PP2 and myosin phosphatase allows for 14-3-3 disassociation and nuclear import 
of the HDAC3/SMRT/N-CoR/HDAC class IIa complex, and subsequent target gene 
repression [132]. 
The class IIb enzymes (HDAC6 and 10) are significantly different from all the 
other classic HDACs.  HDAC6 and 10 both contain two deacetylase domains, although 
the second domain in HDAC10 is vestigial.  Given that HDAC6 and 10 do not self-
associate and are catalytically active as monomers, it has been hypothesized that the 
duplication of the catalytic domain may satisfy the requirement for dimerization or 
association [92]. 
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HDAC6 is primarily cytosolic [133] while HDAC10 is primarily nuclear [134].  
HDAC6 contains an additional C-terminal zinc finger domain which can interact with 
mono and polyubiquitin and ubiquinated proteins [133].  HDAC6 has been determined to 
be instrumental in the formation of the aggresome in the misfolded protein response as 
well as being critical to the induction of the heat shock proteins [134, 135].  A major 
target of HDAC6 is alpha-tubulin.  Surprisingly only one of HDAC6’s two catalytic 
domains possesses alpha-tubulin deacetylase activity and inhibitors must be targeted to 
this domain for alpha-tubulin hyperacetylation to occur [136].  HDAC6 null mice 
demonstrate global hyperacetylated alpha-tubulin [89].  This was an interesting finding 
because the level of HDAC6 in tissues did not correlate with the level of alpha-tubulin 
acetylation.  This may reflect the ability of HDAC6 to associate with the class III HDAC, 
SirT2, to deacetylate alpha-tubulin [137] and the possibility that total loss of HDAC6 may 
abrogate SirT2 deacetylase ability. 
Class IV – The class IV group includes only one member: HDAC11.  HDAC11 is 
the smallest of the classical HDACs, with 4/5 of the protein being dedicated to its 
catalytic domain [100].  It has been designated in its own class because it shares 
sequence similarities with both the class I and class II HDACs [92].  HDAC11 can be 
nuclear or cytoplasmic and is mainly expressed in the heart, brain, skeletal muscle and 
testis [100].  HDAC11 does not participate in any of the classic HDAC class I or II 
complexes but does interact with HDAC6 [138]. 
HDAC11 expression is especially high in neutrophils compared to other myeloid 
cells and HDAC11 deficiency leads to a more aggressive neutrophil population [139].  
Recent research indicates that HDAC11 is an immune attenuator, with deficiency or 
inhibition of HDAC11 leading to suppression of IL-10 and development of more rapid 
and potent graft-versus-host disease [140]. 
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Conclusions  
 The HDAC proteins are an ancient and highly conserved family of proteins that 
almost certainly predate their role as histone acetytransferases and transcriptional 
repressors [93].  The 18 HDAC proteins coded in the human genome are non-redundant 
and perform a highly diverse array of functions throughout the cell.  Individual HDAC 
expression can be ubiquitous or tissue specific.  The intracellular location of HDAC 
protein can be nuclear, cytoplasmic, or both, dependent upon the specific HDAC protein.  
HDACs deacetylate both histone and non-histone proteins and act as master epigenetic 
regulators of gene transcription.  Histone deacetylation results in “closed” chromatin and 
repression of transcription.  However, HDAC inhibition often leads to increases in the 
expression of certain genes.  These phenomena can be attributed to the targeting of 
HDACs to specific regions of the genome via repressor complexes.   
 
Objective of the Work 
 A successful clinical trial must begin with a solid foundation in pre-clinical study.  
As previously covered in this work, strong evidence from several studies supports the 
combination of HDACi with Gem as an effective treatment modality in PDAC.  
Unfortunately, because of treatment-related toxicity HDACi have not taken a place in the 
PDAC treatment arsenal.  Selective HDACi, when utilized correctly, can target the HDAC 
proteins that are dysregulated in cancer as well as HDACs that are relied on by cancer 
cells.  As previously referenced in this work, cancer cells can lose their ability to manage 
HDAC inhibition, producing a significant tolerance disparity between healthy and 
transformed cells. 
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 In the same way that the thousands of genetic alterations in PDAC can be 
distilled down to four critical protein mutations/deletions, the dysregulation in HDAC 
expression can be narrowed to 2 classes of HDACs.  Research has identified HDAC 
classes I and II as being disproportionately dysregulated in PDAC [141, 142].  Beginning 
with 6 members of the class I and II HDACs, a tailor-made HDACi cocktail can be 
developed based on the vulnerabilities of PDAC. 
 Our study was conducted in two phases.  Phase I aimed to elucidate the HDAC 
protein(s) required by PDAC cells for survival and proliferation.  Next, selective targeting 
of required HDACs in combination with Gem was performed to determine if the identified 
proteins were also responsible for pan-HDACi synergy with Gem.  The final goal of our 
work was to build a custom drug regimen to target the specific HDACs critical for PDAC 
maintenance and whose targeting was essential for synergy with Gem.  Phase II of our 
study was focused on determining if our novel HDACi/Gem combination would be 
tolerated in an animal model. 
 
Experimental Design 
 
 Human PDAC cell culture models were utilized to study tumor response to HDAC 
loss through siRNA knockdown (KD) and pharmacological inhibition.  PDAC cell lines 
were also utilized for synergy and apoptosis studies with drug combinations.  After a 
successful drug combination was discovered, athymic nude mice were employed to 
establish toxicity and efficacy in an animal model. 
 Human PDAC cell lines were selected to represent different combinations of the 
four most common genetic mutations in PDAC (KRAS, CDKN2A, p53, and SMAD4) 
[143].  Western blotting was performed on all cell lines selected to establish endogenous 
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expression of the class I and II HDACs studied (Figure 5). 
 Critical class I and II targets were determined by a combination of siRNA KD and 
class I and II targeted inhibitors.  MTT assay was performed on HDAC KD cells in the 
absence and presence of drugs.  Differences in cellular proliferation as measured by 
MTT assay were utilized to narrow down critical HDAC drug targets, and increasingly 
specific HDACi were tested.  Drugs were administered for 72 h to allow for three cell 
divisions under Gem exposure, and cells were always exposed to drug at the beginning 
of their logarithmic growth phase (Materials and Methods).  These two precautions 
allowed us to evaluate Gem at its peak performance, yielding a more accurate 
evaluation of synergy between Gem and HDACi. 
 Knockdown (KD) experiments were performed on the human PDAC cell lines 
MiaPaCa2 and Capan1 given their amenability to siRNA uptake and targeted protein 
KD. Knockdown of each individual class I and II HDAC was determined to be ideal at 48 
h (Figure 11).  HDAC KD cells were plated in 96-well plates 24 h after siRNA exposure 
and drug treatment was initiated the following day (48 h after siRNA exposure) to allow 
for maximum combination effect.  As shown in Figure 11, very little to no targeting 
overlap between different HDAC proteins was observed with our KD method (Materials 
and Methods). 
 As previously mentioned in this work, published data demonstrate that pan-
HDACi can induce cell cycle arrest in both G1 and G2/M phases.  Gem, however, has 
been determined to halt the cycle only in G1 phase.  Cell cycle analysis was performed 
to determine if the G1 and G2/M cell cycle arrest could be reproduced with the pan-
HDACi, panobinostat, and to determine if panobinostat effects could be recapitulated 
with targeted HDACi. 
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 In PDAC, HDACi are believed to induce significant increases in apoptosis [144, 
145].  Apoptosis has been proposed to be a major mechanism in the synergy observed 
between Gem and HDACi, via HDACi’s ability to target non-dividing PDAC cells in 
addition to the actively dividing cells targeted by Gem. AnnexinV-FITC staining was 
therefore utilized to determine the effects of combination treatments over each HDACi 
alone and GEM alone on apoptosis.  Apoptotic effects were also evaluated by Western 
Blot analysis of cleaved PARP and Caspase3. 
 Finally, successful synergistic drug combinations identified using cell line models 
were evaluated for efficacy and toxicity in animal models.  Athymic nude mice were 
subcutaneously and/or orthotopically implanted with GFP-labeled human PDAC tumor 
cells and, after allowing enough time for tumors to establish, subjected to identified 
treatment regimens and observed for any toxic effects (Materials and Methods).  Mice 
were also evaluated for tumor burden and metastasis to determine if drug regimens 
provided measurable benefit in vivo. 
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Results 
  
The studies performed in this work explored the potential of HDACi as valuable clinical 
tools for the treatment of PDAC.  Previous clinical studies demonstrated that the pan-
HDACi, Panobinostat, is an effective chemotherapeutic in combination with gemcitabine, 
despite significant off-target toxicity [88].  Utilizing CalcuSyn computer software in 
conjunction with MTT assays, we recreated the synergy/additivity observed between 
Panobinostat and gemcitabine in four human PDAC cell lines: MiaPaCa-2, Capan-1, 
CFPAC, and T3M4 (Figure 2i / Table 1/2).  These experiments involved combination of 
Panobinostat and gemcitabine at equipotent ratios of their respective EC50 values in 
PDAC cell culture and analysis via MTT assay (Figure 2i, Table 2).  The MTT results 
were then analyzed using CalcuSyn computer software to determine Combination Index 
(CI) values for the drug combinations.  A CI value equal to 1 indicates the drugs are 
additive and no synergy has been observed, CI values over 1 indicate antagonism and 
values under 1 indicate synergy (Table 1).  The closer the CI value is to zero the better 
the synergy.  The Panobinostat/gemcitabine combination studies demonstrated synergy 
in two of the four PDAC cell lines tested, Capan-1 and CFPAC (Figure 2i).  T3M4 cells 
demonstrated additivity while the MiaPaCa-2 cells showed antagonism with the 
Panobinostat/gemcitabine combination.  In agreement with previously published 
literature, Panobinostat was able to induce apoptosis in the low nanomolar range, as 
evidenced by cleavage of PARP and Caspase 7 on Western blot analysis (Figure 3).  
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Although Panobinostat has demonstrated significant potential in the clinic, 
especially in combination with traditional chemotherapies, off-target toxicities have 
prevented it from being utilized for pancreatic cancer therapy.  As is further explored in 
the Discussion section of this work, the toxicity related to Panobinostat is most likely due 
to targeting HDACs which are not necessary for PDAC treatment.  Panobinostat is a 
highly potent pan-HDACi, which targets all 11 classical HDACs in the low nanomolar 
range [146].  As discussed in the Introduction section, HDAC1, 2, 3, 4, 5, and 6 are often 
over-expressed in PDAC [141].  Experiments in this work focused on these six HDACs 
to identify those that are critical to Panobinostat’s anti-tumor response and synergy with 
gemcitabine, and in an effort to reduce/eliminate off-target toxicities of HDAC inhibition.  
 
Effects of Mocetinostat and LMK-235 in PDAC Cell Lines 
Initial experiments were performed to determine if inhibition of HDACs 1, 2, 3, 4, 
5 and/or 6 is sufficient to recapitulate the synergy/additivity observed with the 
gemcitabine/Panobinostat combination. The requirement for HDACs 1, 2, and 3 was 
explored using Mocetinostat [147], an inhibitor of HDACs 1, 2, and 3.  Experiments to 
determine the requirement for HDACs 4, 5, and 6 used the potent inhibitor LMK-235 
[144] and Droxinostat was tested to evaluate the effects of combined inhibition of 
HDACs 3, 6, and 8 [145] (Table 3).  Cells were treated with the maximum biologically 
relevant dose (10 µM) of the HDAC inhibitors, and effects of these agents were 
compared with those of Panobinostat on the apoptosis markers PARP and Caspase 7 
(Figure 3).  Experiments in MiaPaCa2 cells revealed that Panobinostat, Mocetinostat, 
and LMK-235 similarly increased PARP and Caspase 7 cleavage at 24 h, while 
Droxinostat was unable to induce these effects (Figure 3).   
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The similarity between the effects of Mocetinostat, LMK-235 and Panobinostat led us to 
further explore the more selective drugs in PDAC cell culture models.  
Mocetinostat and LMK-235 showed antitumor activity in PDAC cell lines with 
ED50 values in the high nanomolar to low micromolar range (Table 4).  The specificity of 
the drugs for individual HDACs was confirmed by Western blot analysis of protein 
acetylation.  Consistent with its ability to inhibit HDACs 1, 2, and 3, Mocetinostat 
upregulated acH3(K9) (a common histone target indicating HDAC inhibition), but failed 
to upregulate the HDAC6 specific activity marker ac-α-tubulin in PDAC cells (Figure 4).  
LMK-235 upregulated acH3(K9) and ac-α-tubulin, consistent with its ability to inhibit 
HDACs 4, 5, and 6.  Follow-up studies confirmed that the HDACs targeted by 
Mocetinostat and LMK-235 are expressed in the PDAC cell culture models used in this 
study:  HDACs 1-6 are expressed at various levels in all five cell culture models 
analyzed (MiaPaCa2, Capan-1, BxPC3, Panc1, and CFPAC) (Figure 5). 
Given that HDACs 1-6 are the most commonly overexpressed HDACs in PDAC 
[141, 142], we hypothesized that Panobinostat’s anti-tumor activity in PDAC may be due 
to inhibition of these six enzymes.  If our hypothe sis was correct, the combination of 
Mocetinostat and LMK-235 should prove synergistic.  As shown in Figure 6, the 
combination of Mocetinostat and LMK-235 demonstrated significant synergy, with CI 
values ranging from approximately 0.5 (synergistic) in BXPC3 cells to 0.8 (weakly 
synergistic) in CFPAC cells.   
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 Having established a similar activity profile for Panobinostat and the 
Mocetinostat/LMK-235 combination, cell cycle analysis was performed to further 
elucidate the mechanism of action of these agents in PDAC cells.  A major mechanism 
underlying the activity of HDACi, including Panobinostat, is their ability to halt cell cycle 
progression at both the G1/S and the G2/M checkpoints [148].  Studies have 
demonstrated that pan-HDACi such as Vorinostat and Belinostat exert their influence on 
the cell cycle by inducing the expression of p21 protein [83, 149].  Further evidence has 
suggested that the synergy between HDAC inhibition and gemcitabine lies in the ability 
of HDACi to upregulate p21 independently of p53 and to subsequently arrest the cell 
cycle at the G2/M checkpoint [79].   
 Western blot analysis confirmed the ability of Panobinostat to upregulate p21 
protein in CFPAC cells (Figure 7).  Using p53 null HCT116, we further demonstrated 
that the effect is p53-independent, a point of contention in the literature [150, 151].  Flow 
cytometric analysis of propidium iodide-stained, nocodazole-synchronized CFPAC cells 
confirmed Panobinostat’s ability to induce cell cycle arrest at both the G1/S and G2/M 
cell cycle checkpoints (Figure 8).  In contrast, Mocetinostat showed a significantly 
reduced ability to induce arrest at the G1/S checkpoint (Figure 8).  LMK-235, however, 
demonstrated a similar profile to Panobinostat in its ability to arrest the cell cycle at both 
the G1 and G2/M phases (Figure 8).  The cell cycle analysis provided evidence that the 
two drugs, Mocetinostat and LMK-235, work through different pathways within the cell.  
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Consistent with our cell cycle data, the combination of Mocetinostat and LMK-
235 increased γH2AX expression at 4, 12, and 24 h after exposure (Figure 9).  Studies 
have demonstrated that γ-H2AX signaling occurs as a result of double strand DNA 
breaks, which can coincide with cell cycle arrest [152].  When double strand breaks are 
detected, the specialized histone, H2AX, is recruited to the break site and rapidly 
phosphorylated at Ser 139 to become γ-H2AX, where it then acts as a scaffold for the 
attachment of the DNA repair machinery [153].   
 To determine if the synergy/additivity observed between Panobinostat and 
gemcitabine [83] could be attributed to the class I HDACs inhibited by Mocetinostat or 
the class II HDACs targeted by LMK-235, we tested the effects of each drug in 
combination with gemcitabine (Figure 10).  We observed additivity to antagonism in both 
experiments, indicating that the synergy observed between Panobinostat and 
gemcitabine most likely reflects combined inhibition of at least one HDAC from two 
different classes.   
 Next, we tested a combination of Mocetinostat and LMK-235 with gemcitabine to 
determine if inhibition of HDAC’s 1-6, or a selection of these 6 HDACs, could account for 
the synergy observed between Panobinostat and gemcitabine.  As demonstrated in 
Figure 2i, the Mocetinostat/LMK-235/gemcitabine combination (M/L/G) showed 
significant synergy in four PDAC cell lines.  The M/L/G combination promoted increased 
PARP cleavage over each drug alone, or a combination of Mocetinostat and LMK-235 
(Figure 2ii).   Given the effects of the Mocetinostat/LMK-235 combination, our next step 
was to determine if fewer than the 6 HDACs targeted by Mocetinostat and LMK-235 
could deliver the same PDAC toxicity and gemcitabine synergy. 
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Increased HDAC Selectivity Recapitulates Antitumor Efficacy in 
PDAC Cell Culture Models  
 To identify the HDACs critical for Mocetinostat/LMK-235 synergy in PDAC cells, 
we used siRNA technology to knockdown each individual HDAC targeted by these drugs 
(Materials and Methods).  As shown in Figure 11, we were able to successfully knock 
down all six HDACs in the Capan-1 cell model, with no observable reduction/alteration in 
untargeted HDACs.  Knockdown was less complete in the MiaPaCa-2 cell line, 
especially in the case of HDAC6 (Figure 11).  To model inhibition of HDACs 1, 2, and 3 
by Mocetinostat or HDACs 4, 5, and 6 by LMK-235, relevant HDACs were silenced in 
combination.  Successful targeting was demonstrated by the activity markers ac-α-
tubulin (HDAC6 activity marker) and ac-H3(K9) (general histone acetylation marker) 
(Figure 12). 
Although individual and combined knockdown of HDACs was largely successful 
in MiaPaCa-2 and Capan-1 cells (Figures 11 and 12), MTT assays (72 h) revealed no 
significant reduction in cellular viability over non-targeting control treatment as 
demonstrated by MTT assay (Figure 13).  Possible explanations for the differential 
effects of pharmacological inhibition and knockdown of HDACs on cell viability include: 
(a) a higher level of inhibition than obtainable with siRNA-mediated knockdown is 
needed for the toxicity seen with pharmacological inhibition of these HDACs.  This 
explanation is supported by data shown in Figure 14, which demonstrate a significantly 
more pronounced increase in ac-H3(K9) in the drug-treated cells compared with the 
HDAC knockdown cells; (b) the long half-life of HDAC proteins may allow compensation 
for the loss of HDAC activity by activation of other genes.  For example, HDAC2 has a 
half-life greater than 12 h [154], whereas histone acetylation begins to increase in PDAC 
cells within 30 m of exposure to pharmacological HDACi [75].   
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Cycloheximide studies in our laboratory reinforce the published HDAC half-life 
data, with HDACs 1 and 4 not being significantly reduced until 24 h after cycloheximide 
exposure (Figure 15).  The rapidity with which HDACi exert their effects in PDAC cell 
models is demonstrated by our studies in MiaPaCa-2 cells treated with the combination 
of LMK-235 and Mocetinostat, with increases in ac-α-tubulin observed after just 1 h of 
drug treatment (Figure 15); and (c) Mocetinostat and LMK-235 have off-target effects on 
the viability of PDAC cells that are independent of their effects on HDACs.  
Follow-up studies employed a strategy in which drug treatment was combined 
with HDAC knockdown.  Varying concentrations of Mocetinostat or LMK-235 were 
administered to PDAC cells silenced for the HDACs targeted by the partner drug.  If the 
ED50 values for the drug treatment were significantly reduced with HDAC knockdown 
over non-targeting siRNA, we could conclude that the synergy observed between 
Mocetinostat and LMK-235 was the result of HDAC inhibition and not an off-target effect.   
Initial experiments were performed in HDACs 1, 2, and 3 knockdown MiaPaCa-2 
cells (Materials and Methods) treated with the HDAC 4, 5, and 6 inhibitor LMK-235. The 
ED50 for LMK-235 was modestly affected by HDAC 3 knockdown and significantly 
affected by combined knockdown of HDACs 1, 2, and 3 (Figure 16).  As demonstrated 
in Table 5, the ED50 for LMK-235 was reduced by nearly 70% in the context of HDAC 1, 
2, and 3 knockdown.  These results pointed to combined class I and II HDAC inhibition 
as the basis for Mocetinostat/LMK-235 synergy in PDAC cells. 
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Next, we sought to determine if combined inhibition of all three class I HDACs 
targeted by Mocetinostat (HDACs 1, 2, and 3) is required for synergy with LMK-235.  
Given that HDACs 1 and 2 are paralogs and share 82% sequence homology [113] and 
that HDAC 1 is reported to compensate for the loss of HDAC 2 [155]; we hypothesized 
that inhibiting only HDACs 1 and 2 may yield similar results to inhibiting HDACs 1, 2, and 
3.  Our analysis of MiaPaCa-2 and Capan-1 cells revealed that inhibition of HDACs 1 
and 2 is sufficient for synergy, with the ED50 for LMK-235 in cells with knockdown of 
HDACs 1 and 2 being nearly identical to that in cells with HDACs 1, 2, and 3 knockdown  
(Figure 17).  As demonstrated in Table 6, knockdown of HDACs 1 and 2 reduced the 
ED50 value of LMK-235 by 61% in MiaPaCa-2 cells and by 34% in the Capan-1 cell line. 
Consistent with these findings, Western blot analysis of MiaPaCa-2 revealed a similar 
increase in cleaved PARP and γH2AX activation with LMK-235 in combination with 
HDAC1/2 knockdown or in combination with HDAC1/2/3 knockdown (Figure 18).     
 Additional experiments explored the effects of Mocetinostat treatment in the 
context of HDACs 4, 5 and 6 knockdown.  Studies in the Capan1 PDAC cell line 
identified HDAC6 as a key target, since the effects of the drug were potentiated to the 
same extent by HDAC 4/5/6 knockdown and knockdown of HDAC6 alone (Figure 19, 
Table 7).  Thus, the synergy between Mocetinostat and LMK-235 appears to further 
involve inhibition of HDAC6. 
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Taken together, our findings using pharmacological inhibitors and knockdown of 
HDACs, individually and in combination, indicated that the synergy observed between 
Mocetinostat and LMK-235 is the result of HDAC1, 2, and 6 inhibition.  Importantly, 
treatment of Capan1 PDAC cells with gemcitabine in the context of HDAC1, 2, and 6 
knockdown resulted in a significant reduction in gemcitabine’s ED50, with a decrease in 
the effective dose of the chemotherapeutic of 86% (Figure 20 / Table 8).  The basis for 
Mocetinostat/LMK-235 synergy in MiaPaCa2 cells could not be established, likely 
because of incomplete knockdown of HDAC6 in this cell line.     
 
Synergistic effects of HDAC1, 2, and 6 inhibition and  
Gemcitabine in PDAC cells 
 Based on the identification of HDACs 1, 2, and 6 as key targets in the antitumor 
activity of HDACi in PDAC, we evaluated the effects of the HDAC-specific drugs, 
Romidepsin (ROM) (HDAC1, 2 inhibitor) [156] and ACY-1215 (ACY) (HDAC6 inhibitor) 
[157], alone and in combination.  As previously reported, ROM is a highly potent inhibitor 
of HDAC1 and 2 [156].  ACY is a next generation, highly specific HDAC6 inhibitor with 
minimal activity against HDACs 1, 2, 3, 4, 5, 7, and 9, but with slight activity against 
HDAC8 [158].  
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Romidepsin was determined to be highly toxic to PDAC cell lines, demonstrating 
ED50 values in the low nanomolar range in all cell lines tested (Table 9).  In agreement 
with published work [82, 159], pharmacologic inhibition of HDAC6 by ACY-1215 was not 
toxic to MiaPaCa-2 or Capan-1 PDAC cells when administered at concentrations 
sufficient to yield full HDAC6 inhibition [159-161].  While MTT assays yielded ED50 
values near 5 µM for these cell lines (Figure 21), Western blot analysis pointed to a 
maximum HDAC6 inhibitory activity of ACY-1215 at 1 µM, which was the dose we 
utilized in our studies (Figure 22).  Given the inability of ACY-1215 to produce a 
dose/effect relationship at the study dose of 1 µM (Figure 23), ACY-1215 was added at 
a fixed dose of 1 μM instead of varying doses at equipotent ratios along with 
gemcitabine and Romidepsin.  
 In initial experiments, MiaPaCa-2 and Capan-1 cells were treated with a 
combination of Romidepsin and Gemcitabine (R/G) to establish synergistic activity 
(Figure 24).  Notably, the effects of the Romidepsin/gemcitabine combination were 
significantly enhanced by the addition of 1 µM ACY-1215 (Figure 24).  The effects of 
these drugs were recapitulated in Panc1, BxPC3, and CFPAC PDAC cells (Table 10), 
supporting the generality of the effect. 
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The Romidepsin/gemcitabine/ACY-1215 (R/G/A) combination also increased 
γH2AX levels, pointing to the induction of double-stranded DNA breaks, as observed 
with the Mocetinostat/LMK-235 combination (Figure 14).  The triple combination was 
also able to elicit an increase in apoptosis as indicated by elevated levels of cleaved 
caspase 3 and PARP on Western blots (Figure 25) and by an increase in AnnexV 
positive staining cells detected by flow cytometric analysis (Materials and Methods) 
(Figure 26). 
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Verifying HDACs 1, 2, and 6 as critical for synergy with 
gemcitabine in PDAC 
 To fully establish HDAC1, 2, and 6 inhibition as the basis for the toxicity of 
Panobinostat in PDAC cells and the synergy between Panobinostat and Gemcitabine, 
we performed additional HDAC knockdown studies and drug substitutions. 
 HDAC6 knockdown in combination with Romidepsin treatment yielded significant 
synergy with gemcitabine in both the MiaPaCa-2 and Capan1 cell lines (Table 11).  We 
also tested the HDAC6 inhibitor Nexturastat (Figure 22), which was substituted for ACY-
1215 in combination with Romidepsin and gemcitabine, resulting in strong synergy in 
three of the four cell lines evaluated (Table 12i).  HDAC 1/2 knockdown shifted the ACY-
1215 ED50 curve left in Capan-1 and MiaPaCa-2 cells, pointing to a synergistic 
interaction (Figure 21).  Impressive synergy was also observed when Mocetinostat 
(HDAC 1/2/3 inhibitor) was substituted for Romidepsin (HDAC 1/2 inhibitor) in ACY-
1215/gemcitabine combinations (Table 12ii).  Finally, the HDAC6 specific inhibitor WT-
161, which at higher concentrations will also target HDACs 1 and 2 [162], was utilized as 
proof-of-principle that a single drug targeting HDACs 1, 2, and 6 will synergize with 
gemcitabine. Significant synergy was observed in four of the 5 PDAC cell lines tested 
(Table 13).  The lack of synergy in Capan-1 cells could be the result of an intrinsic 
toxicity of WT-161 in this cell line.  Consistent with this explanation, while Capan-1 cells 
displayed the lowest ED50 value for WT-161, Panc1 cells which demonstrated the 
greatest synergy also had the highest ED50 value for the drug.  It is possible that Capan-
1 cells were being killed by WT-161 at doses too low to sufficiently inhibit HDACs 1/2 
and trigger a synergistic interaction with gemcitabine.   
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Combined HDAC1, 2, and 6 inhibition and gemcitabine for the 
treatment of PDAC in vivo 
 After establishing that inhibition of HDACs 1, 2, and 6 is responsible for 
Panobinstat’s toxic and synergistic effects in PDAC cell lines in vitro, toxicity trials in 
mice were required to determine the safety of the Romidepsin/Gemcitabine/ACY-1215 
combination.  Based on reported doses in mice of 2 mg/kg twice weekly for Romidepsin, 
30-50 mg/kg five days per week for ACY-1215, and twice weekly gemcitabine at 100-
125 mg/kg (e.g. [163-167]), we demonstrated that 2 mg/kg Romidepsin and 40 mg/kg 
ACY-1215 plus 125 mg/kg gemcitabine are non-toxic, as reflected in similar weight gain 
to vehicle-treated mice over a three-week period (22% ± 1.4% vs. 21% ± 1.1%) (Figure 
27). 
 We next conducted efficacy studies in mice bearing PDAC xenografts (Material 
and Methods) (UNMC IACUC approval code: 18-177-01-FC).  To model gemcitabine in 
the clinic, mice were treated with gemcitabine at 640 mg/kg twice weekly, which is 80% 
of the maximum tolerated dose.  The Romidepsin/ACY-1215 combination had a mild 
inhibitory effect on the growth of Capan-1 xenografts (Figure 28).  Although gemcitabine 
was initially able to inhibit tumor growth in this model, the effect was temporary, and 
tumor growth resumed as a resistant population of cells grew out.  Notably, treatment 
with gemcitabine in combination with Romidepsin and ACY-1215 markedly inhibited this 
later growth of tumors, leading to a statistically significant reduction in tumor size by 24 
days compared with gemcitabine treatment alone.  Thus, consistent with the in vitro 
data, selective HDAC1, 2, and 6 inhibitors are able to potentiate the effects of 
gemcitabine on PDAC tumors in vivo, blocking the ability of these tumors to grow 
following prolonged gemcitabine treatment. 
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Studies of Panobinostat in Combination with the Survivin 
Transcriptional Repressor YM155 
 Note: Shane Laschanzky was initially under the supervision of Dr. Michael G. 
Brattain. From 2014 until Dr. Brattain’s death in February 2016, he performed studies on 
the combination of HDAC inhibition and transcriptional repression of survivin as an 
approach for cancer therapy. The results of these studies are summarized below. 
 
  The Inhibitor of Apoptosis Protein (IAP), survivin, is unique in that it is the 
smallest IAP and has not been demonstrated to bind caspase directly.  Instead, survivin 
exerts its anti-apoptotic activity by binding to XIAP, also an IAP, and inhibiting its 
ubiquitin-induced degradation [168].  Survivin expression in PDAC is a negative 
prognostic marker and is associated with more advanced disease [169]. Previous work 
in the Brattain laboratory demonstrated a relationship between pan-HDAC inhibition and 
re-expression of Transforming Growth Factor Beta Receptor 2 (TGFβ-R2), leading to a 
reduction in survivin protein levels and an increase in apoptosis in colon cancer cell lines 
[170].  Unpublished work in colon cancer models demonstrated a synergistic relationship 
between YM155, a survivin transcriptional repressor, and the pan-HDAC inhibitor, 
Belinostat.  Given that TGFβ signaling is disrupted in over 50% of PDAC tumors [171], 
we hypothesized that the survivin transcriptional repressor, YM155, would also 
synergize with the pan-HDAC inhibitor panobinostat in PDAC cell models.   
YM155, an imidazolium-based small molecule inhibitor, has demonstrated high 
selectivity against survivin at the core gene promotor level [172].  Published work from 
the Brattain laboratory showed that YM155 treatment reduces survivin mRNA 
expression in both colon and PDAC cell models [173].  Thus, a combination of YM155 
and panobinostat would be expected to target survivin expression via two independent 
pathways, potentially decreasing the emergence of resistance mechanisms.   
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Initial results were promising.  Western blot analysis revealed a reduction in both 
XIAP and survivin protein expression in MiaPaCa2 cells after 24 h exposure to 
Panobinostat (Figure 29).  However, follow-up studies failed to demonstrate a reduction 
in survivin protein with the combination of YM155 and Panobinostat (Figure 30). 
Instead, survivin protein levels appeared to increase with higher doses of Panobinostat 
and with the combination of YM155 and Panobinostat at levels which individually would 
reduce survivin protein expression (Figure 30).  Given these disappointing results, the 
change in supervisor, and our inability to obtain YM155 from Astellas Pharma, Inc., the 
survivin pan-HDACi studies were discontinued.      
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Utilizing Novel Multi-Target Small Molecule Inhibitors in 
Combination with HDACi and Gemcitabine 
  Three experimental compounds designed by the Donald Durden group and 
SignalRX (University of California, San Diego) were provided to our laboratory for 
evaluation in PDAC cell lines, and to determine synergistic potential utilizing our 
combinatorial methodology.  The three compounds: SRX3225, SRX3177 and SF2523, 
were characterized in PDAC cell lines for individual EC50 values, protein targets, and 
combination potential. 
  The first compound evaluated, SRX-3225, is a first-in-class triple inhibitor of PI3K 
(isoforms: p110α, p110ү, and p110δ), BRD4-1/2, and, HDAC6 [174].  Western blot 
analysis for acetyl-α-tubulin confirmed that SRX-3225 is an HDAC6 inhibitor in PDAC 
(Figure 31). However, this drug demonstrated no toxicity in PDAC cell lines at 
concentrations up to 20 mM (data not shown).  Further studies with SRX-3225 were not 
conducted. 
 The second compound, SRX-3177, is another triple action inhibitor with activity 
against BET, PI3Kα, PI3Kү, PI3Kδ, and CDK4/6 (Durden et al., unpublished).  SRX-
3177 was developed to target these molecules in silico, utilizing proprietary “CRIMP” 
technology with the intent of creating synthetic lethality by targeting tumor cell growth 
signaling [174, 175].  Initial characterization by MTT assay revealed SRX-3177 to be 
effective in the mid nanomolar range (Table 14).   
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Published studies have demonstrated BET inhibitors to synergize with 
Romidepsin in both cutaneous T-cell lymphoma [176] and urothelial carcinoma models 
[177].  Given these published results, we tested the combination of SRX-3177 and 
Romidepsin in PDAC cell lines.  The initial SRX-3177/Romidepsin combination trials did 
not demonstrate significant synergy in four of the five PDAC cell lines tested, with only 
the Panc1 cells demonstrating any significant synergy (Figure 32).  This avenue was not 
further explored. 
 SF-2523, or Morpholinothienopyrane, is the most well characterized compound 
provided to us by the Durden laboratory.  SF-2523 is a dual inhibitor of PI-3K (p110α, 
p110ү, and p110δ) and BRD4.  Combined inhibition of PI3K and BRD4 proteins 
effectively blocks MYC expression and activation, while also promoting MYC 
degradation in cell line and animal models of neuroblastoma [178].  To determine if SF-
2523 would be a good candidate drug for PDAC therapy, we evaluated its effects in five 
human PDAC cell lines and were able to demonstrate reduced viability in MTT assays 
(Table 14).  SF-2523 demonstrated toxicity in the low micromolar range in all PDAC cell 
lines tested (Table 14).  Initial studies into SF-2523’s activity in PDAC using Western 
blot analysis demonstrated a marked reduction in pAKT (S473) levels by 30 minutes, 
confirming strong inhibition of PI3K activity (Figure 33).  Given SF-2523’s promising 
results as a candidate for PDAC treatment, we tested it’s effects in combination with 
gemcitabine as a basis for justification of future clinical trials.  SF-2523 demonstrated 
synergy with gemcitabine in the three PDAC cell lines tested at ED90 and in two of the 
three cell lines at ED75 (Table 15).  
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Discussion  
Introduction   
  Chemotherapy is the use of drugs to destroy cancer cells.  Chemotherapeutic 
drugs target tumor cell growth, survival, and metastasis. Tumors acquire their growth 
advantage, ability to avoid apoptosis and metastatic potential via dysregulation of genes 
and signaling pathways.  Importantly, these advantages come at a cost, creating 
vulnerabilities that can be exploited.  An example of inherent vulnerability in tumor cells 
is their susceptibility to HDACi (as discussed in Chapter 2, tumor cells are up to ten 
times more susceptible to HDACi over non-transformed cells).  The focus of this work 
has been to elucidate the most effective way to utilize HDACi drugs to target PDAC cells 
while minimizing toxicity. 
Although pan-HDACi have demonstrated potential in solid tumors, including 
PDAC, significant dose limiting toxicities have prevented their use in the clinic [179].  It 
has been proposed that the dose limiting toxicities associated with pan-HDACi may be 
avoided through targeted HDAC inhibition.  This notion has led to the development of 
targeted HDACi for the treatment of multiple cancers including PDAC [180].  However, 
as discussed in Chapter 2 of this work, the success of this strategy has been limited to 
date.   
  The studies described in this dissertation were based on the concept that a better 
understanding of the specific HDAC(s) required for maintenance and progression of 
PDAC, combined with the use of more selective inhibitors targeting these HDAC(s), 
would provide improved therapeutic benefit while minimizing off-target toxicity to normal 
cells. Little is known regarding the role of the 11 classical HDAC proteins in PDAC 
development and maintenance.  As explored in Chapter 1, although there is some 
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redundancy between HDAC proteins within each HDAC class, there is little to no 
redundancy between HDACs of different classes.  HDAC proteins can also be 
ubiquitously expressed or cell-type specific (given the diversity of HDAC proteins in 
normal cells, we hypothesized that the HDAC protein repertoire of PDAC is likely to be 
highly specific). Targeted inhibition of HDACs expressed in PDAC was, therefore, used 
to identify HDACs that are essential for PDAC survival as well as HDACs whose 
disruption may lead to off-target toxicities.  The uncoupling of efficacy from dose limiting 
toxicity was the ultimate rationale for this work.   
 A major treatment advantage associated with HDACi is related to their ability to 
work synergistically with traditional chemotherapies such as gemcitabine, and to reverse 
acquired drug resistance (Chapter 2).  The ability of HDACi to work synergistically with 
gemcitabine provided another avenue to explore, both as a novel way to increase 
gemcitabine’s efficacy but also to reduce off-target effects and toxicities by reducing 
gemcitabine’s effective dose.  In the context of this work, for selective HDAC inhibitors to 
have clinical potential, they must meet three criteria: significantly less off-target effects 
and toxicities in comparison to pan-HDACi, at least comparable efficacy to that of pan-
HDACi, and the ability to work synergistically with gemcitabine.   
Moving the Field Forward  
Over the past decade, a number of phase I clinical studies of pan-HDACi in 
combination with traditional chemotherapies have been performed in solid tumors, 
including PDAC  [88, 181-183].  This strategy has not yielded beneficial results, largely 
because of significant off-target cardiac toxicities associated with pan-HDACi treatment.  
However, despite the failure of pan-HDACi treatment for solid tumors in the clinic, 
exploration of the potential of new pan-HDACi drugs is ongoing and there is continued 
interest in bringing these agents to clinical trial as quickly as possible [184, 185].  The 
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experiments presented were designed to help move the field forward by demonstrating 
the potential of an attractive alternative: the use of tailored HDAC inhibition utilizing 
HDAC isoform-specific inhibitory drugs.   
Many of the off-target cardiac toxicities associated with pan-HDACi can be 
attributed to inhibition of the class IIa HDACs 4, 5, 7, and/or 9.  Class IIa HDACs are 
significantly more tissue-specific and have been implicated in off-target effects of the 
pan-HDACis such as heart arrythmia [186].  Interestingly, two recent studies utilizing the 
HDAC1, 2, and 3 inhibitors Mocetinostat or Tacedinaline in combination with 
gemcitabine for the treatment of patients with advanced PDAC have come to a similar 
conclusion as our study; HDAC1, 2, and 3 inhibitors in combination with gemcitabine 
yield no advantage over each drug alone [187, 188] (Figure 10).  In contrast, a 
combination study in PDAC cell lines utilizing CG200745 or Chidamide has yielded 
promising results.  Chidamide, an HDAC1/2/3/6/10 inhibitor currently in phase II trials for 
peripheral T-cell lymphoma [189], demonstrated synergistic effects with gemcitabine in 
BxPc3 and CFPAC PDAC cells as well as in BxPc3 mouse xenograft models [52].  
Based on our work, it can be inferred that the basis for the failure of Mocetinostat and 
Tacedinaline and of the success of Chidamide was in their differential ability to inhibit 
HDAC6.  However, based on past knowledge, patients treated with Chidamide at levels 
high enough to affect solid tumors such as PDAC, will most likely experience significant 
negative off-target effects, including cardiac toxicities (due to inhibition of HDAC3 by 
Chinamide and subsequent induced loss of function of HDAC 4, 5, 7 and 9) (Figure 1).   
Since HDAC3 provides the deacetylase activity for the class IIa enzymes, 
inhibition of HDAC3 directly affects the activity of the class IIa enzymes (HDACs 
4/5/7/9).  Given the critical importance of HDAC3 to the activity of the class IIa HDACs, 
any inhibitor targeting HDAC3 (such as Chidamide) should be considered an 
103 
 
HDAC3/4/5/7/9 inhibitor.  This becomes important when factoring in the mitigating 
abilities of specific-HDACi in comparison to pan-HDACi in relation to off-target toxicities.  
The distinction between selective and pan-HDACi must be clearly delineated to avoid 
the significant side effects that restrict pan-HDACi from use clinically.  For example, the 
HDAC1,2,3,6,10 inhibitor Chidamide is presented as a novel class I and IIb inhibitor.  
However, in reality, Chidamide is a class I and II inhibitor with the ability to inhibit 9 of the 
11 classical HDACs.  Given its comprehensive inhibitory profile, clinical side effects 
similar to pan-HDACi are expected.  
Evidence from this work and others suggests that inhibition of HDAC3 without 
inhibition of HDAC6 abrogates the synergistic effects of HDACi in combination with 
gemcitabine.  Consistent with this notion, while the HDAC1/2 inhibitor Romidepsin 
effectively synergizes with gemcitabine (Figure 24 and [190]), the combination of the 
HDAC1/2/3 inhibitor Mocetinostat and gemcitabine is antagonistic, an effect that can be 
reversed with the addition of an HDAC6 inhibitor such as LMK-235 or ACY-1215 (Figure 
2i, Table 12ii).  This phenomenon is also apparent in the ability of pan-HDACi such as 
Panobinostat, Belinostat, or Vorinostat to synergize with gemcitabine in PDAC cell 
models [55, 88, 191].   
Our study not only demonstrates the expendability of HDAC3 inhibition for 
effective PDAC therapy, but also presents a strong case for HDAC3 as being 
responsible for a loss, or at least significant reduction, in synergy with gemcitabine.   
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Evidence for a Critical Role of Combined HDAC1, 2, and 6 
Inhibition for Achieving HDACi Success in PDAC  
 Our study indicates that inhibition of HDACs 1, 2, and 6 opens a therapeutic 
window in which lower effective doses of both HDAC inhibitors and traditional 
chemotherapeutics such as gemcitabine will be effective. 
 Although we did not fully explore the mechanisms behind the promising effects of 
HDAC1, 2, and 6 inhibition in combination with gemcitabine in PDAC, the cooperativity 
between HDAC1, 2, and 6 inhibition is not unexpected.  Several explanations for this 
cooperativity can be found in the literature.  Firstly, HDAC1 is overexpressed in 40% of 
PDACs and has been associated with a significantly worse prognosis [192, 193].  
Similarly, HDAC2, a well-established tumor promoter, is also overexpressed in a majority 
of PDACs [193].  Given the reported ability of HDAC1 to compensate for HDAC2 loss 
[155], a need for simultaneous inhibition of these two enzymes is expected.  HDACs 1 
and 2 may also play a role in epithelial to mesenchymal transition given that they have 
been reported to downregulate E-cadherin in PDAC cells [194].  E-cadherin loss has 
also been attributed to resistance to gemcitabine [195], providing a possible explanation 
for inhibition of HDACs 1 and 2 as critical to the HDACi/gemcitabine synergy observed in 
our study. 
 The connection between HDAC2 and HDAC6 is also well established in the 
literature.  Interactions between HDAC2 and 6 have been implicated in loss of the 
primary cilium during PDAC tumorigenesis through a mechanism that involves HDAC2-
mediated upregulation of Aurora A and subsequent increased phosphorylation/activation 
of HDAC6 [196].   
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 Recent progress in understanding the role of the oncogenic properties of mutant 
p53 [197] has provided another explanation for the success of simultaneous HDAC1, 2, 
and 6 inhibition in PDAC.  HDAC6 inhibition selectively destabilizes mutant p53 protein 
while promoting the acetylation and activity of wild-type p53 [198, 199].  HDAC1 and 2 
inhibition, in turn, downregulates both mutant and wild-type p53 at the transcriptional 
level [200].  Given that, as previously stated, p53 is mutated in over 75% of PDAC 
tumors, simultaneous inhibition of HDAC1, 2, and 6 leading to maximum silencing of p53 
signaling should yield significant anti-tumor effects.  Interestingly, our experiments with 
Panobinostat clearly demonstrate this phenomenon.  In Figure 7, Western blot analysis 
clearly shows that Panobinostat treatment reduces p53 expression in PDAC cells.  
 While inhibition of HDACs 1, 2, and 6 is important for the treatment of PDAC, of 
equal importance is the protection of the remaining 8 classical HDACs.  As previously 
stated, pan-HDACi have not been further developed for the clinical management of solid 
tumors due to significant off-target effects.  By targeting HDAC1, 2, and 6 specifically, 
we have created a drug regimen which provides the anti-tumor effects of pan-HDACi 
and the synergistic effects of pan-HDACi with gemcitabine, while preventing off-target 
toxicities associated with pan-HDACi. 
 
Alternate Combinatorial Strategies to Reduce the Effective Dose 
of Pan-HDACi and Minimize Off-Target Effects 
 In 2013, at the onset of this study, many of the studies exploring selective HDACi 
in synergistic combinatorial treatment with traditional chemotherapies had not been 
published or were not yet well known.  The dominant strategy for bringing HDACi to the 
clinic for the treatment of solid tumors was to reduce the effective dose of pan-HDACi 
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through combination with a small molecule inhibitor targeting a relevant signaling 
pathway. Given the success of pan-HDACi in hematopoietic malignancies such as T-cell 
lymphoma [201] and multiple myeloma [202], it was hypothesized that the key to 
success in solid tumors was to shift the effective dose in solid tumors closer to that in 
hematological tumors.  Multiple studies utilizing small molecule inhibitors targeting 
different signaling pathways related to HDACi were designed and tested [203, 204].   
In the same vein as these efforts, our study was originally designed to combine 
the small molecule inhibitor of survivin transcription, YM155, with the pan-HDACi, 
Panobinostat for the eventual triple combination with gemcitabine in a clinical trial.  As 
stated previously, the death of Dr. Michael Brattain, compounded with an unexplained 
increase in survivin expression in response to Panobinostat or Panobinostat/YM155 
combination treatment (Figure 30) and our inability to obtain YM-155 from Astellas, 
prevented this work from moving forward. 
The increase in survivin protein we observed with high doses of Panobinostat 
may be explained by the inhibition of HDAC6.  Survivin is not typically expressed in non-
dividing normal cells; however, it is expressed in nearly all human cancers [205].  In 
normal cells, survivin acts as a regulator of mitosis.  The protein is upregulated during 
the G0/G1 phase of the cell cycle and inhibition or downregulation of survivin prevents 
cell cycle progression into S-phase [206].  During normal development, survivin is 
acetylated by CREB-binding protein and restricted to the nuclear compartment where it 
cannot bind to XIAP and interfere with apoptosis [207].  In cancer, HDAC6 deacetylates 
survivin allowing it to enter the cytoplasm and assume its anti-apoptotic role [208].  In 
our Panobinostat/YM155 study, the observed increase in survivin may have reflected an 
accumulation of nuclear protein.  Cellular fractionation experiments and analysis of the 
nuclear compartment for survivin could answer this question.  Antibodies against ac-
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survivin(K129) could also be utilized in conjunction with cellular fractionation to further 
establish this phenomenon as the explanation for the increase in survivin expression 
observed in response to pan-HDACi treatment.   
The use of the experimental compounds provided by Dr. Donald Durden 
reinforced the need for a tailored approach to combination treatment, especially in the 
context of HDACi.  The HDAC6/BRD4/PI3K inhibitor SRX3225 demonstrated no toxicity 
when tested on our panel of PDAC cell lines.  This result is in contrast to published 
literature demonstrating a strong synergistic relationship in PDAC between JQ1 (a BRD4 
inhibitor) with SAHA (a pan-HDACi) [209].   
Given the adverse effects associated with pan-HDACi in the clinic, if the 
BRD4/HDAC combination is to be further explored in PDAC, specific inhibition should be 
employed.  This work provides a template for that study.  Investigators following our 
methodology could substitute JQ1, or any other BRD4 inhibitor, for gemcitabine and 
conduct selective HDAC inhibition and siRNA knockdown studies. 
Taken together, the compounds provided by Dr. Durden failed to support the 
Bromodomian and Extraterminal Domain (BET) proteins as targets for PDAC toxicity.  
The BET protein BRD4 is targeted by each of the three drugs tested in our PDAC panel, 
with very diverse results ranging from no toxicity to significant toxicity in these cells.  The 
BET proteins are epigenetic readers which are reported to be the link between 
acetylated transcription factors and histones, for the activation of RNA polymerase II 
[210].  The idea behind the combination of a BET inhibitor with a PI3K inhibitor and/or a 
CDK4/6 inhibitor is to prevent epigenetic changes associated with acquired drug 
resistance.  In our study of SF2523, a reasonable ED50 value was obtained in all five cell 
lines indicating PDAC toxicity (Table 14).  Effects of the second-generation drug 
SRX3177, which also targets CDK4/6 (Table 14) were even more promising. 
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Studies have identified CDK4/6 inhibitors as powerful anti-neoplastic drugs [211], 
whose effects are rapidly bypassed by other signaling mechanisms such as PI3K/AKT 
signaling [212, 213].  SRX3177 was designed to address potential drug-induced 
resistance mechanism via inhibition of epigenetic signaling networks activated by the 
tumor though BET inhibition and blockade of the PI3K signaling pathway.  Consistent 
with our findings with SRX3225 in PDAC cell lines, the combination of Romidepsin with 
SRX3177 did not produce significant synergy.  Taken together, these results suggest 
that HDAC inhibition is not a necessary or beneficial addition to CDK4/6/BET/PI3K 
combinatorial strategies.         
Conclusions and Future Directions 
 The overarching question that drove the experiments performed in this study 
was; Could a rational reduction in the number and type of HDACs targeted by HDACi be 
the key to unlocking their potential in the clinic?  Our work shows some promise in 
achieving this goal. 
Multiple studies and clinical trials mentioned previously in this work have shown 
that pan-HDAC inhibitors such as Panobinostat can be highly effective in managing 
PDAC tumors.  However, these drugs have never been utilized successfully in the clinic 
due to off-target toxicities.  The off-target toxicities are frequently attributed to the higher 
doses required for efficacy in solid tumors.   
At the onset of this work, few studies had addressed the potential of using 
combinations of selective HDACi to identify specific activities of HDACs in tumors and 
design novel therapeutic strategies with reduced off-target effects.  Over the years it took 
to complete this work, however, multiple studies were published utilizing more specific 
HDACi with successful results [52, 53].  What sets our work apart from other comparable 
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contemporary studies is the in-depth approach used to identify HDACs of interest.  
Class-specific small molecule inhibitors were used alone and in combination and effects 
were further explored using siRNA-mediated knockdown of relevant HDAC(s).  Results 
were fully established using a combination of HDAC-specific small molecule inhibitors 
and HDAC knockdown strategies. This work provides a roadmap for other scientists to 
follow, not only as a formula for the development and utilization of more advanced 
HDAC targeting drugs but also as a general strategy for elucidating HDACs of interest in 
the context of tumor sequencing and personalized medicine.   
Further studies are needed to determine the mechanism of HDAC1, 2, and 6 
inhibition both in relation to anti-tumor effects in PDAC, but also to the synergy with 
gemcitabine.  Determination of the underlying cellular pathways responsible for the 
observed benefits of HDAC1, 2, and 6 inhibition with gemcitabine may yield new insights 
which could lead to an even more potent and effective drug combination.   To futher 
explore the activity of HDAC1, 2, and 6 in combination with gemcitabine, genetic rescue 
experiments should be performed in addition to the KD experiments presented in this 
work.  For example, to confirm the results obtained in Figure 20 (HDAC1, 2, and 6 KD in 
combination with gemcitabine), re-expression of the target HDACs leading to an 
increase in the effective dose of gemcitabine (to levels comparable with the non-target 
control group) would reinforce HDACs 1, 2, and 6 as the proteins responsible for the 
observed synergy.     
  Additional animal studies are also required to determine if selective inhibition of 
HDACs 1, 2, and 6 in combination with gemcitabine influences metastasis, or if it has an 
ability to prolong survival.  Successful pancreatic orthotopic studies, as well as studies 
with the KRAS mouse model would justify human PDX tumor studies and eventually 
clinical trials. 
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Summary   
The HDACs are an ancient and evolutionarily conserved family of proteins, 
predating the histones themselves.  Eukaryotes have co-evolved with naturally occurring 
HDACi, developing pathways to overcome the effects of these substances, pathways 
that are frequently lost in cancers such as PDAC.  Given the immense potential of 
HDACi in the treatment of cancer, approaches must be developed to implement the use 
of these drugs in the clinic.  Tailoring specific HDAC inhibitory combinations to PDAC 
provides an avenue to decrease the effective dose of these drugs and concurrently 
alleviate their toxicity.  In a disease such as PDAC, where curative surgery is rarely an 
option and chemotherapeutics offer the only hope for disease management, successful 
utilization of HDACi offers a chance to prolong life with minimal negative side effects. 
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Materials and Methods 
 
Cell Culture 
   
  Human PDAC cell lines, MiaPaCa-2 (ATCC CRL-1420), Capan-1 (ATCC HTB-
79), BxPC-3 (ATCC CRL-1867), CFPAC-1 (ATCC CRL-1918), T3M-4 (Riken RCB1021), 
and PANC-1 (ATCC CRL-1469) were maintained in McCoy’s 5A medium supplemented 
with pyruvate, vitamins, amino acids, antibiotics, and 10% fetal bovine serum at 37 ºC in 
5% CO2.  Where indicated, cells were treated with Panobinostat (Sellechem, Houston, 
TX, USA), Droxinostat (Sellechem), Mocetinostat (Sellechem), LMK-235 (Sellechem), 
ACY-1215 (MedChem Express, Monmouth Junction, NJ, USA), Romidepsin (MedChem 
Express), and/or gemcitabine (Sagent Pharmaceuticals, Schaumburg, IL, USA) in 
DMSO (Sigma, St. Louis, MO) (except gemcitabine, which was in sterile water).  For 
controls, cells were treated with vehicle; DMSO concentrations in the final culture 
medium were ≤ 0.001%. 
Western Blot Analysis   
  Cells were lysed in 50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 1% Nonidet P-40, 2 
mM EDTA, 0.1% SDS, 50 mM NaF, 10 mM Na3V04, 1 mM phenylmethylsulfonyl 
fluoride, 25 µg/mL β-glycerophosphate, and one protease inhibitor tablet             
(Complete Protease Inhibitor Cocktail, Roche, Tuscon, AZ, USA, Cat: 11697498001)  
and extracts (30 µg protein) were analyzed by Western blotting as described. Protein 
concentration was determined by Pierce BCA Protein Assay Kit (Thermo Fisher 
Waltham, MA, USA, Cat: 23225).  Protein separation and transfer was performed with 
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the BioRad Mini-Cell tank and powerpack equipment (BioRad, Hercules, CA, USA).  
After lysis and protein extraction, a 15 µL aliquot containing 30 µg of protein and loading 
buffer (BioRad) was loaded into each well of either 12% or 15% gels poured in-house 
(BioRad) and run at 100 V until the blue loading buffer line reached the bottom of the 
gel-plate.  Proteins were then transferred to “Amersham” nitrocellulose blotting 
membrane (0.45 µM pore size) (GE Healthcare, Incheon, South Korea, Cat: 10600023) 
via a 90 min transfer at 500 mA on ice.  Following blocking with 5% milk in TBST, blots 
were incubated with one of the following primary antibodies from Cell Signaling: [PARP: 
95425; Caspase 7: 128275; GAPDH: 5174; HDAC1: 3565; HDAC2: 51135; HDAC3: 
39495; HDAC4: 7628; HDAC5: 204585; HDAC6: 76125; acetyl-α-tubulin (Lys40): 5335; 
acetyl-histone 3: 9649; cleaved caspase 3: 9664].  Following transfer, membranes were 
cut (guided by molecular weight markers) to facilitate probing for multiple proteins at 
specific molecular weights.   
MTT Assays  
 Initially, PDAC cells were plated in 96-well cell culture plates (Thermo Fisher 
Scientific, Waltham, MA, USA) at densities ranging from 100-1000 cells/well to establish 
cell line-specific growth curves.  Cells were then plated at densities consistent with the 
logarithmic growth phase occurring concurrently with drug treatments (100 cells/well - 
Capan1, 250 cells/well - MiaPaCa2 and BxPc3, 500 cells/well – CFPAC and Panc1). 
 Twenty-four hours after initial plating, cell medium was replaced, and drugs or 
vehicle were administered.  Cells were then allowed to grow for 72 h.  After the 72-h 
drug treatment, MTT assays were performed.  The assays consisted of addition of 50 µL 
of 3-(4,5 Dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT Reagent) (Sigma) 
and incubation for 2 hours at 37 °C.  Next, the MTT reagent was aspirated and replaced 
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with 100 µL DMSO (Sigma) and the plates were analyzed via optical density at 570 nm 
using the ELx808™ Absorbance Microplate Reader (BioTek, Winooski, VT, USA).  
Results were interpreted via GraphPad analytical software (GraphPad Software, San 
Diego, CA, USA). 
siRNA Knockdown  
 Human ON-TARGETplus SMARTpool siRNAs against HDACs 1, 2, 3, 4, 5, and 6 
and non-targeting siRNA were purchased from Dharmacon (HDAC 1: L-003493-00-
0005, HDAC 2: L-003495-02-0005, HDAC 3: L-003496-00-0005, HDAC 4: L-003497-00-
0005, HDAC 5: L-003498-00-0005, HDAC 6: L-003499-00-0005, Non-Target: D-001810-
01-50) .  ON-TARGETplus SMARTPool siRNAs consist of four siRNAs that are designed 
and modified to increase specificity and reduce off-target effects.  MiaPaCa-2 and 
Capan-1 human PDAC cells were transfected with 37.5 pmol each of targeted and non-
targeting siRNA using Lipofectamine 3000 (Thermo Fisher Scientific, Cat: L3000015) 
according to the manufacturer’s protocol.  After 48 h, cells were analyzed by Western 
blotting or subjected to drug treatment and MTT assay. 
Cell Cycle Analysis 
  CFPAC cells were plated in 6-well culture dishes (Falcon/Corning, Tewksburry, 
MA, USA) at 500k cells/well and allowed to grow for 48 h.  Next, the cells were treated 
with either drug or DMSO control at 0.001% for 24 h.  Nocodazole-treated cells were 
exposed to 1 µM Nocodazole (Sigma, Cat: M1404) in DMSO concurrently with HDAC 
inhibitor exposure.  72 h after initial plating, cells were trypsinized utilizing the previously 
reported cell culture methodology and reagents.  Approximately 1 million cells were 
transferred to 2 mL microcentrifuge tubes and pelleted via benchtop microcentrifuge at 
10,000 g for 1 min at room temperature.  The supernatant was decanted, and 1 mL 
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ethanol was added dropwise to each tube under gentle vortexing.  The cell/ethanol 
mixture was then incubated at 4 ºC for 30 min followed by centrifugation as above.  
Ethanol was decanted and cells were washed once with 1 mL PBS and again spun 
down.  Next, 1 mL of fresh Telford reagent (1.681 mg EDTA (Sigma), 1.34 mg RNAse A 
at 93 U/mg (Sigma), 2.5 mg propidium iodide (Sigma), 50 mL Triton X-100 (Sigma)), and 
50 mL PBS were added to each vial and allowed to incubate for 1 hour.  After 
incubation, cells were spun down, resuspended in 3 mL of PBS and filtered into 5 mL 
flow cytometry tubes (Falcon) on ice.  Cells were then analyzed via flow cytometry 
immediately after filtration.  Propidium iodide staining was performed in accordance with 
the protocol suggested by the UNMC Flow Cytometry Facility and analysis was 
performed under supervision of the Core Facility staff.  
Annexin V-FITC Assay 
 MiaPaCa-2, Capan-1, and PANC-1 cells were plated at 2.5 X 105 in 10 cm 
culture plates and treated with HDAC inhibitors and/or gemcitabine after 24 h.  Following 
30 h of drug treatment, apoptosis (cell surface phosphatidylserine) was assessed using 
the Annexin V-FITC Apoptosis Detection Kit (Sigma, Cat: APOAF) as instructed by the 
manufacturer.  Flow cytometry was performed in the Flow Cytometry Core Facility at the 
University of Nebraska Medical Center (UNMC). 
Mouse Xenograft Studies  
  All animal experiments were performed under a protocol approved by the IACUC 
at UNMC (approval code:  18-177-01-FC).  Capan-1 cells (5 X 106) were injected into the 
flanks of athymic NCr-nu/nu mice (Charles River, Durham, NC, USA).  After tumors had 
reached ~1000 mm3, 16 mice per group were treated with intraperitoneal injection of 
either vehicle, 2 mg/kg Romidepsin plus 40 mg/kg ACY-1215, 640 mg/kg gemcitabine, 
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or 2 mg/kg Romidepsin plus 40 mg/kg ACY-1215 plus 640 mg/kg gemcitabine for 3 
weeks.  Treatment schedules were as follows: 40 mg/kg ACY-1215, daily; 2 mg/kg 
Romidepsin, twice weekly; 640 mg/kg gemcitabine, twice weekly.  Tumors were 
measured daily using calipers, and volumes were estimated using the formula 3.14/6 X 
length X width2. 
Analysis of Drug Interactions  
  Analysis of drug combination effects and combination index (CI) was performed 
using the method of Chou and Talalay [214, 215].  Cell lines were treated with drugs 
individually and in combination at equipotent ED50 ratios for each drug for 72 h, and CI 
values were calculated from the results of MTT assays using Calcusyn software (Biosoft, 
Cambridge, UK).  CI > 1 indicates antagonism between drugs, CI = 1 indicates additive 
effects, CI < 1 indicates drug synergy. 
Statistics 
 Curve fitting and estimation of ED50 values for drug treatments were performed 
using GraphPad Prism Software (GraphPad Software).  Statistical differences were 
determined by Student’s t test using Microsoft Excel (p < 0.05 was considered 
statistically significant).  For xenograft growth, descriptive statistics and mean plot 
(counts, means, standard deviations, minimums, and maximums) were used to 
summarize the tumor growth for treatment days and groups.  Measurements of each 
outcome observed over treatment days were considered as repeated measures and fit 
with a linear mixed effect model with AR(1) structure for correlations to evaluate the 
change of the outcome measurement values (tumor growth) between treatment groups.  
In addition, pairwise comparisons of outcome measurements in treatment groups were 
compared in each measurement time point and adjusted for multiple comparisons with 
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Tukey’s method.  Significance was determined by including interaction terms of 
treatment day and group in the mixed effect models.  All analyses were done using SAS, 
Version 9.4 (SAS, Cary, NC, USA).  p < 0.005 was considered statically significant. 
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